[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 620
1. Jain VS, Singh KK, Shrivastava R, Saumsundaram KV, Sarje MB, Jain SM: Radical radiotherapy treatment (EBRT + HDR-ICRT) of carcinoma of the uterine cervix: outcome in patients treated at a rural center in India. J Cancer Res Ther; 2007 Oct-Dec;3(4):211-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical radiotherapy treatment (EBRT + HDR-ICRT) of carcinoma of the uterine cervix: outcome in patients treated at a rural center in India.
  • AIM: To report the outcome of carcinoma of the uterine cervix patients treated radically by external beam radiotherapy (EBRT) and high-dose-rate (HDR) intracavitary radiotherapy (ICRT).
  • MATERIALS AND METHODS: Between January 1997 to December 2001, a total of 550 newly diagnosed cases of carcinoma of the uterine cervix were reported in the department.
  • Out of the 550 cases, 214 completed radical radiotherapy (EBRT + HDR-ICRT) and were retrospectively analyzed for presence of local residual disease, local recurrence, distant metastases, radiation reactions, and disease-free survival.
  • The median follow-up time for all patients was 43 months (range: 3-93 months) and for patients who were disease free till the last follow-up it was 59 months (range: 24-93 months).
  • The 5-year disease-free mean survival rate was 58%, 44%, 33%, and 15%, with 95% confidence interval of 48 to 68, 37 to 51, 24 to 35, and 6 to 24 for stages I, II, III, and IV, respectively.
  • There were 62 (28.97%) cases with local residual disease, 35 (16.3%) developed local recurrence/distant metastases, 17 (7.9%) developed distant metastases, and 9 (4.2%) had local recurrence as well.
  • DISCUSSION AND CONCLUSION: The overall outcome was poor in advanced stage disease, but might be improved by increasing the total dose, decreasing overall duration of treatment, and by adding chemotherapy in patients with disease limited to the pelvis.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy


2. Fu JM, McCalmont T, Yu SS: Adenosquamous carcinoma of the skin: a case series. Arch Dermatol; 2009 Oct;145(10):1152-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the skin: a case series.
  • BACKGROUND: Adenosquamous carcinoma is an uncommon cutaneous malignant neoplasm with mixed glandular and squamous differentiation and a propensity for aggressive clinical behavior.
  • OBSERVATIONS: Of 27 patients diagnosed as having adenosquamous carcinoma, 19 were men and 5 were immunosuppressed.
  • Squamous and glandular differentiation was characteristic.
  • CONCLUSIONS: Adenosquamous carcinoma is best considered as a locally aggressive high-risk subtype of cutaneous squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841403.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Suzuki S, Ishikawa K: Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer. J Infect Chemother; 2009 Oct;15(5):335-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S-1 is an oral 5-fluorouracil (5-FU) anticancer agent and has shown promising effects in the treatment of a wide range of carcinomas, including head and neck cancer.
  • Thirteen patients with squamous cell carcinoma (SCC) and 3 patients with non-SCC who had recurrent/metastatic disease received S-1 monotherapy as outpatients.
  • One patient with nasopharyngeal undifferentiated carcinoma and 1 patient with maxillary adenosquamous carcinoma showed complete response (CR), while all SCC patients showed stable disease (SD) or progressive disease (PD).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Palliative Care. Tegafur / therapeutic use

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856075.001).
  • [ISSN] 1437-7780
  • [Journal-full-title] Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • [ISO-abbreviation] J. Infect. Chemother.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


Advertisement
4. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H: Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol; 2010 Dec 27;2(12):419-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, ICC was largely classified into adenocarcinoma and rare variants.
  • The former is a tubular or micropapillary adenocarcinoma while the latter involves the intrahepatic large bile duct.
  • Hepatic progenitor cell or stem cell phenotypes such as neural cell adhesion molecule expression are frequently expressed in the bile ductular type.
  • Intraductal type includes papillary and tubular neoplasms of the bile duct (IPNBs and ITNBs) and a superficial spreading type.
  • IPNB and ITNB show a spectrum from a preneoplastic borderline lesion to carcinoma and may have pancreatic counterparts.
  • At invasive sites, IPNB is associated with the conventional bile duct ICC and mucinous carcinoma.
  • Rare variants of ICC include squamous/adenosquamous cell carcinoma, mucinous/signet ring cell carcinoma, clear cell type, undifferentiated type, neuroendocrine carcinoma and so on.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2008 Jun;215(2):175-83 [18393368.001]
  • [Cites] Mod Pathol. 2001 May;14(5):527-32 [11353065.001]
  • [Cites] J Clin Gastroenterol. 1994 Jun;18(4):335-42 [8071522.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1739-45 [15185318.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1333-43 [17058219.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):350-8 [16360234.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(4):288-91 [14598147.001]
  • [Cites] Hepatol Res. 2007 Oct;37 Suppl 3:S478-86 [17931207.001]
  • [Cites] Histopathology. 1980 Jul;4(4):391-400 [6253379.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):651-8 [11584359.001]
  • [Cites] World J Hepatol. 2009 Oct 31;1(1):35-42 [21160963.001]
  • [Cites] Lab Invest. 2009 Nov;89(11):1261-74 [19721413.001]
  • [Cites] Hepatol Res. 2008 Apr;38(4):325-34 [18093122.001]
  • [Cites] J Hepatol. 2006 Dec;45(6):856-67 [17030071.001]
  • [Cites] Microsc Res Tech. 1997 Sep 15;38(6):552-70 [9330346.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):829-41 [19218340.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1243-54 [16741522.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2145-9 [9610693.001]
  • [Cites] Cancer. 1977 Jan;39(1):232-46 [64293.001]
  • [Cites] Pathol Int. 2010 Jun;60(6):419-29 [20518896.001]
  • [Cites] Pathol Int. 2010 Jul;60(7):516-9 [20594273.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):701-9 [17431410.001]
  • [Cites] Curr Gastroenterol Rep. 2006 Feb;8(1):30-7 [16510032.001]
  • [Cites] Pathol Int. 2005 Apr;55(4):180-8 [15826244.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1193-203 [15316319.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1337-44 [14691921.001]
  • [Cites] Histopathology. 2007 Sep;51(3):390-400 [17553067.001]
  • (PMID = 21191517.001).
  • [ISSN] 1948-5182
  • [Journal-full-title] World journal of hepatology
  • [ISO-abbreviation] World J Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3010511
  • [Keywords] NOTNLM ; Adenocarcinoma / Bile duct / Bile ductule / Intraductal neoplasm / Intrahepatic cholangiocarcinoma
  •  go-up   go-down


5. Tudor A, Sestan B, Jonjic N, Miletic D, Hadzisejdic I, Prpic T, Rakovac I: Solitary metastasis of the patella in the differential diagnosis of anterior knee pain. West Indian Med J; 2010 Jan;59(1):110-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary metastasis of the patella in the differential diagnosis of anterior knee pain.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Adenosquamous / secondary. Lung Neoplasms / pathology. Pain / diagnosis. Patella / pathology
  • [MeSH-minor] Aged, 80 and over. Biopsy. Diagnosis, Differential. Diagnostic Imaging. Humans. Male

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931928.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Jamaica
  •  go-up   go-down


6. Vinh-Hung V, Bourgain C, Vlastos G, Cserni G, De Ridder M, Storme G, Vlastos AT: Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer; 2007;7:164
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Histopathology is a cornerstone in the diagnosis of cervical cancer but the prognostic value is controversial.
  • Registry area, age, marital status, race, year of diagnosis, tumor histology, grade, stage, tumor size, number of positive nodes, number of examined nodes, odds of nodal involvement, extent of surgery, and radiotherapy were evaluated in Cox models by stepwise selection using the Akaike Information Criteria.
  • From 1973 to 2002, number of cases dropped from 1,100 new cases/year to 900/year, but adenocarcinomas and adenosquamous carcinoma increased from 100/year to 235/year.
  • Statistically significant variables for both overall and cause-specific mortality were: age, year of diagnosis, race, stage, histology, grade, hysterectomy, radiotherapy, tumor size and nodal ratio.
  • Cause-specific mortality hazard ratios by histological type relatively to non-microinvasive squamous cell carcinoma were: microinvasive squamous cell carcinoma 0.28 (95% confidence interval: 0.20-0.39), carcinoma not otherwise specified 0.91 (0.79-1.04), non-mucinous adenocarcinoma 1.06 (0.98-1.15), adenosquamous carcinoma 1.35 (1.20-1.51), mucinous adenocarcinoma 1.52 (1.23-1.88), small cell carcinoma 1.94 (1.58-2.39).
  • CONCLUSION: Small cell carcinoma and adenocarcinomas were associated with poorer survival.
  • Increased incidence of adenocarcinomas, their adverse prognosis, and the young age at diagnosis indicate the need to identify women who are at risk.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Age Distribution. Carcinoma, Small Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Continental Population Groups / statistics & numerical data. Female. Humans. Hysterectomy / statistics & numerical data. Incidence. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Radiotherapy / statistics & numerical data. SEER Program. Survival Analysis. United States / epidemiology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):814-21 [12910527.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7215-20 [14612516.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2078-86 [14647141.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):558-62 [14675676.001]
  • [Cites] Curr Treat Options Oncol. 2004 Apr;5(2):119-27 [14990206.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):741-50 [15361180.001]
  • [Cites] Gynecol Oncol. 1979 Apr;7(2):111-22 [437563.001]
  • [Cites] Obstet Gynecol. 1985 Mar;65(3):416-22 [3974967.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1584-93 [2418947.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):145-9 [2807003.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):31-46 [8115784.001]
  • [Cites] J Epidemiol Community Health. 1995 Apr;49(2):153-7 [7798043.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):38-44 [7557613.001]
  • [Cites] J Med. 1995;26(1-2):17-30 [7561528.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):1948-55 [8634986.001]
  • [Cites] Int J Cancer. 2000 May 1;86(3):429-35 [10760834.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1055-62 [11021808.001]
  • [Cites] Eur J Cancer. 2000 Nov;36(17):2266-71 [11072218.001]
  • [Cites] CMAJ. 2001 Apr 17;164(8):1151-2 [11338801.001]
  • [Cites] Lancet. 2001 May 12;357(9267):1490-3 [11377601.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1129-36 [11700260.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2471-83 [11745305.001]
  • [Cites] Gynecol Oncol. 1996 Dec;63(3):304-11 [8946863.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):113-20 [9422324.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Bull Cancer. 1998 Apr;85(4):319-27 [9752295.001]
  • [Cites] Sex Transm Dis. 1999 Apr;26(4 Suppl):S2-7 [10227693.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R680-8 [15535850.001]
  • [Cites] Cancer Detect Prev. 2004;28(6):461-4 [15582270.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):115-9 [11748986.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2002 Feb 10;101(1):64-9 [11803102.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Lancet. 2002 Mar 30;359(9312):1093-101 [11943256.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):412-7 [12402312.001]
  • [Cites] Virus Res. 2002 Nov;89(2):191-9 [12445659.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2428-34 [12460788.001]
  • [Cites] Am J Obstet Gynecol. 2003 Mar;188(3):657-63 [12634637.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):14-9 [12807940.001]
  • [Cites] Biomed Pharmacother. 2003 Mar;57(2):67-77 [12854514.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):118-20 [12861148.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):282-9 [12893188.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):528-34 [15502807.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2005 Aug;19(4):485-500 [16150389.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9 [16172231.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1301-4 [16265348.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):171-5 [16404371.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1481-95 [16206285.001]
  • [Cites] Cancer Causes Control. 2006 Apr;17(3):299-306 [16489537.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Acta Obstet Gynecol Scand. 2006;85(1):106-11 [16521689.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1025-31 [16803480.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/iii-iv [16950024.001]
  • [Cites] Nat Rev Cancer. 2006 Oct;6(10):753-63 [16990853.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1711-42 [16958083.001]
  • [Cites] Nat Rev Cancer. 2007 Jan;7(1):11-22 [17186016.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28 [17237032.001]
  • [Cites] JAMA. 2007 Feb 28;297(8):813-9 [17327523.001]
  • (PMID = 17718897.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1994954
  •  go-up   go-down


7. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD: A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med; 2006 Dec;3(12):e486
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, DNA methylation markers that are highly specific and sensitive for common tumors would be useful for the early detection of cancer, and those required for the malignant phenotype would identify pathways important as therapeutic targets.
  • We identified 132 genes that have 5' CpG islands, are induced from undetectable levels by 5-aza-2'-deoxycytidine in multiple non-small cell lung cancer cell lines, and are expressed in immortalized human bronchial epithelial cells.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 Jan 15;55(2):220-3 [7812947.001]
  • [Cites] Cancer. 1995 May 1;75(9):2400-1 [7712451.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4268-72 [7671234.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2116-28 [16489012.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Cell. 2006 Apr 21;125(2):315-26 [16630819.001]
  • [Cites] Cancer Lett. 2007 Mar 8;247(1):56-71 [16644104.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:32-91 [8806092.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):564-9 [10749912.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):766-74 [9833771.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9027-34 [15604268.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):166-72 [15671542.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):273-82 [15713962.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3654-60 [15897561.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):275-85 [16226703.001]
  • [Cites] Int J Cancer. 2005 Dec 10;117(5):738-45 [15981206.001]
  • [Cites] Bioinformatics. 2005 Nov 1;21(21):4067-8 [16141249.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):216-22 [16408038.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):653-8 [16423993.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Nat Genet. 2006 Feb;38(2):149-53 [16444255.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3105-9 [11306494.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • [Cites] Hum Mol Genet. 2001 Dec 15;10(26):3001-7 [11751682.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):514-9 [11839671.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4822-9 [12101420.001]
  • [Cites] Genet Epidemiol. 2002 Jun;23(1):70-86 [12112249.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Nat Genet. 2003 Mar;33 Suppl:245-54 [12610534.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1114-21 [12615730.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1596-601 [12670910.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:22-7 [12724209.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3104-9 [15131050.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3465-73 [15150099.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Hum Mol Genet. 2004 Sep 1;13(17):1969-78 [15254011.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5982-7 [15342377.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):707-17 [15343277.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6410-5 [15374948.001]
  • [Cites] Oncogene. 2004 Oct 7;23(46):7669-78 [15361840.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Oncogene. 1992 Jan;7(1):171-80 [1311061.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jul;10(3):183-9 [7522041.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Cancer Res. 1995 Jan 1;55(1):28-30 [7805035.001]
  • [CommentIn] PLoS Med. 2006 Dec;3(12):e479 [17194184.001]
  • (PMID = 17194187.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE5816
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / U01 CA084971; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / U01CA84971
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNA1 protein, human; 0 / Cyclin A; 0 / Cyclin A1; 0 / DNA-Binding Proteins; 0 / MSX1 Transcription Factor; 0 / MSX1 protein, human; 0 / Transcription Factors; 148814-46-4 / BNC1 protein, human; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC1716188
  •  go-up   go-down


8. Kim SK, Shim HS, Lee KG, An HJ, Lee KR, Cho NH: Glassy cell carcinoma predominantly commits to a squamous lineage and is strongly associated with high-risk type human papillomavirus infection. Int J Gynecol Pathol; 2009 Jul;28(4):389-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glassy cell carcinoma predominantly commits to a squamous lineage and is strongly associated with high-risk type human papillomavirus infection.
  • SUMMARY: Glassy cell carcinoma (GCC) has been believed to have originated from reserve or uncommitted cells as a poorly differentiated adenosquamous carcinoma.
  • GCC could not be precisely categorized, but was committed to squamous lineages and was strongly associated with high-risk type HPV infection.
  • [MeSH-major] Carcinoma, Adenosquamous / virology. Papillomavirus Infections / complications. Uterine Neoplasms / pathology. Uterine Neoplasms / virology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cell Lineage. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Polymorphism, Restriction Fragment Length. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors


9. Smoot RL, Zhang L, Sebo TJ, Que FG: Adenosquamous carcinoma of the pancreas: a single-institution experience comparing resection and palliative care. J Am Coll Surg; 2008 Sep;207(3):368-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas: a single-institution experience comparing resection and palliative care.
  • BACKGROUND: Adenosquamous carcinoma is a rare malignancy of the exocrine pancreas.
  • STUDY DESIGN: Records were reviewed for patients with adenosquamous pancreatic cancer evaluated during the years 1985 to 2003.
  • RESULTS: Twenty-three patients were identified with adenosquamous carcinoma of the pancreas.
  • CONCLUSIONS: The retrospective review of our single-institution experience with resection and palliative care for adenosquamous cancer of the pancreas has demonstrated a longer survival for patients that can undergo an R0 resection.
  • [MeSH-major] Carcinoma, Adenosquamous / surgery. Palliative Care. Pancreatectomy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy
  • [MeSH-minor] Aged. Disease Progression. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Length of Stay. Male. Middle Aged. Neoplasm Invasiveness. Postoperative Complications / etiology. Postoperative Complications / mortality. Pyloric Antrum / surgery. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18722942.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Coleman DV, Poznansky JJ: Review of cervical smears from 76 women with invasive cervical cancer: cytological findings and medicolegal implications. Cytopathology; 2006 Jun;17(3):127-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To review cervical smears from 76 women which were taken prior to the diagnosis of invasive cervical cancer and to determine the appropriateness of the cytology reports issued on the smears.
  • After microscopic review of the cervical smears, the cases were divided into two groups: Group 1 comprised 50 women who were found to have had at least one false-negative (F/N) smear report prior to the diagnosis of invasive cervical cancer.
  • Forty women developed invasive squamous carcinoma and 10 developed invasive adenocarcinoma.
  • The stage at diagnosis ranged from 1A to stage 4.
  • Nineteen women were diagnosed with squamous cancer, two microinvasive cancer, one glassy cell, two adenocarcinomas, and one with adenosquamous carcinoma.


11. Wydra D, Sawicki S, Wojtylak S, Bandurski T, Emerich J: Sentinel node identification in cervical cancer patients undergoing transperitoneal radical hysterectomy: a study of 100 cases. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):649-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Carcinoma, Adenosquamous / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Hysterectomy. Peritoneum / surgery. Uterine Cervical Neoplasms / radionuclide imaging


12. Fernando HC, Santos RS, Benfield JR, Grannis FW, Keenan RJ, Luketich JD, Close JM, Landreneau RJ: Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg; 2005 Feb;129(2):261-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer.
  • OBJECTIVE: Computed tomographic screening is detecting ever smaller peripheral non-small cell lung cancers.
  • This study compared sublobar resection with lobar resection for stage IA non-small cell lung cancers to assess whether sublobar resection is appropriate treatment for certain lesions.
  • METHODS: A retrospective multicenter study of 291 patients with T1 N0 disease was done.
  • Our experience supports the further investigation of the use of sublobar resection with brachytherapy for peripheral stage IA non-small cell lung cancers smaller than 2 cm.
  • [MeSH-major] Brachytherapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Aged. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15678034.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


13. Kasamatsu T, Onda T, Yamada T, Tsunematsu R: Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma. Int J Gynaecol Obstet; 2005 Apr;89(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma.
  • OBJECTIVE: To identify which patients with locally recurrent cervical carcinoma are potentially curable.
  • All 43 patients with pelvic wall recurrence developed progressive disease.
  • [MeSH-major] Neoplasm Recurrence, Local / therapy. Pelvic Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Female. Humans. Middle Aged. Neoplasm Staging. Pelvic Exenteration. Prognosis. Radiotherapy. Retrospective Studies. Survival Analysis. Treatment Outcome


14. Fukui D, Bando G, Ishikawa Y, Kadota K: Adenosquamous carcinoma with cilium formation, mucin production and keratinization in the nasal cavity of a red fox (Vulpes vulpes schrencki). J Comp Pathol; 2007 Aug-Oct;137(2-3):142-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma with cilium formation, mucin production and keratinization in the nasal cavity of a red fox (Vulpes vulpes schrencki).
  • A diagnosis of adenosquamous carcinoma was made in an 11-year-old red fox.
  • The nasal and oral lesions were composed of adenocarcinomatous cells and squamous cells, the latter predominating in the oral lesions.
  • The marrow of the palatine bone also contained neoplastic tissue, which consisted of cysts and keratin masses surrounded by well-differentiated squamous cells.
  • Neoplastic basal cells and less-differentiated adenocarcinoma cells, which were identifiable by immunolabelling for cytokeratin 5 (CK5) and CK18, were considered to be pluripotential.
  • These cells, which lined tubular structures, were distinct from intermediate cells in mucoepidermoid carcinoma, which can differentiate into squamous and mucin-producing cells but have a nondescript appearance.
  • [MeSH-major] Carcinoma, Adenosquamous / veterinary. Cilia / pathology. Foxes. Keratins / metabolism. Mucins / metabolism. Nose Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645890.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-18; 0 / Keratin-5; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


15. Romero FR, de Castro MG, Garcia CR, Perez MD: Adenosquamous carcinoma of the penis. Clinics (Sao Paulo); 2006 Aug;61(4):363-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the penis.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Penile Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924331.001).
  • [ISSN] 1807-5932
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] Brazil
  • [Number-of-references] 9
  •  go-up   go-down


16. Kodama J, Seki N, Ojima Y, Nakamura K, Hongo A, Hiramatsu Y: Prognostic factors in node-positive patients with stage IB-IIB cervical cancer treated by radical hysterectomy and pelvic lymphadenectomy. Int J Gynaecol Obstet; 2006 May;93(2):130-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariate analysis revealed that non-squamous histology was an independent prognostic factor for disease-free and overall survival rates.
  • In squamous cell carcinomas, the bilateral nature of the positive nodes was found to be a significant factor for disease-free survival rates.
  • In non-squamous cell carcinomas, positive nodes of more than 2 cm in size were found to be a significant factor for disease-free survival rates.
  • CONCLUSION: Non-squamous histology was an independent prognostic factor and chemoradiotherapy did not improve the survival outcomes of the patients in this study population.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / surgery. Uterine Cervical Neoplasms / surgery


17. Hong SM, Kim MJ, Jang KT, Yoon GS, Cho H, Frierson HF, Yu E: Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases. Int J Clin Exp Pathol; 2008;1(2):147-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases.
  • Adenosquamous carcinoma is a rare histologic subtype of extrahepatic bile duct (EBD) carcinoma and limited information is available on its clinicopathologic characteristics.
  • Twelve cases of adenosquamous carcinoma were collected from 3 institutions and their clinicopathologic characteristics were examined and compared with those of 176 EBD adenocarcinomas.
  • The adenocarcinoma component was more often seen at the surface of the tumor (7 of 12 cases, 58%), while the squamous carcinoma component was slightly more frequent at the advanced edge (7 of 12 cases, 58%).
  • Immunohistochemistry, available in 10 cases, revealed that S100A2 was positive in the squamous carcinoma component in all 10 cases (100%), while it was present in the adenocarcinoma component in only 2 of 10 cases (20%, chi-square test, p=0.001).
  • Patients with adenosquamous carcinomas had worse survival (median survival, 11 months) than those with adenocarcinoma (median survival, 32 months; log-rank test, p=0.003).
  • Patients with predominant squamous cell carcinoma component at the leading edge had worse survival than those without it.
  • In conclusion, patients with adenosquamous carcinoma demonstrated worse survival than those with pure adenocarcinoma.
  • S100A2 immunohistochemical staining may be helpful in detecting the squamous component.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):199-206 [17255764.001]
  • [Cites] J Gastroenterol. 2000;35(6):465-71 [10864356.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):802-10 [15959914.001]
  • [Cites] J Gastroenterol. 2005 Feb;40(2):192-9 [15770404.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):258-63 [10211505.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2309-16 [9815629.001]
  • [Cites] Diagn Cytopathol. 1996 Nov;15(4):322-4 [8982588.001]
  • [Cites] Ryoikibetsu Shokogun Shirizu. 1996;(9):61-3 [8705560.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1994 Feb;32(2):161-7 [8164404.001]
  • [Cites] J Gastroenterol Hepatol. 1993 Nov-Dec;8(6):607-12 [8280849.001]
  • [Cites] J Surg Oncol. 1986 Oct;33(2):140-2 [3531727.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] J Surg Oncol. 1980;15(1):29-35 [7421268.001]
  • [Cites] South Med J. 1978 Feb;71(2):216-9 [622635.001]
  • [Cites] Methods Mol Biol. 2005;289:209-22 [15502186.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1515-24 [15467767.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] Biochem Cell Biol. 2004 Aug;82(4):508-15 [15284904.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):300-4 [15278069.001]
  • [Cites] Tumour Biol. 2004 Jan-Apr;25(1-2):31-40 [15192310.001]
  • [Cites] Chir Ital. 2004 Mar-Apr;56(2):289-95 [15152526.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):558-62 [14675676.001]
  • [Cites] Cancer. 2003 May 1;97(9):2196-202 [12712471.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6823-6 [12460893.001]
  • [Cites] Histol Histopathol. 2002 Jan;17(1):123-30 [11813862.001]
  • [Cites] Pathologica. 2000 Oct;92(5):323-6 [11198466.001]
  • [Cites] Int J Mol Med. 2000 Nov;6(5):539-42 [11029520.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):843-50 [17032501.001]
  • (PMID = 18784802.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480552
  • [Keywords] NOTNLM ; Adenosquamous carcinoma / S100A2 / cholangiocarcinoma / extrahepatic bile duct / prognosis
  •  go-up   go-down


18. Lee SW, Kim YM, Kim MB, Kim DY, Kim JH, Nam JH, Kim YT: Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay. Tohoku J Exp Med; 2009 Dec;219(4):277-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-five fresh tumor tissues were obtained from patients with cervical cancer: 47 squamous cell carcinomas, 11 adenocarcinomas, and 7 adenosquamous cell carcinomas.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cell Culture Techniques. Female. Humans. Middle Aged. Recurrence. Treatment Outcome


19. Hori M, Kim T, Murakami T, Imaoka I, Onishi H, Nakamoto A, Nakaya Y, Tomoda K, Tsutsui T, Enomoto T, Kimura T, Nakamura H: MR imaging of endometrial carcinoma for preoperative staging at 3.0 T: comparison with imaging at 1.5 T. J Magn Reson Imaging; 2009 Sep;30(3):621-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of endometrial carcinoma for preoperative staging at 3.0 T: comparison with imaging at 1.5 T.
  • PURPOSE: To prospectively compare magnetic resonance imaging (MRI) at 3.0 T and 1.5 T in the same patients for preoperative evaluation of endometrial carcinoma.
  • MATERIALS AND METHODS: Thirty consecutive patients with endometrial carcinoma underwent MRI at both 3.0 T and 1.5 T as well as surgery.
  • CONCLUSION: 3.0 T MRI is an equivalent imaging modality to 1.5 T imaging for presurgical evaluation of endometrial carcinoma, although not significantly superior to 1.5 T imaging.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Endometrial Neoplasms / pathology. Magnetic Resonance Imaging / methods. Preoperative Care / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711413.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Heterocyclic Compounds; 0 / Organometallic Compounds; 0199MV609F / gadoteridol; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


20. Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA: Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. Int J Surg Pathol; 2005 Oct;13(4):319-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
  • The human epidermal growth factor receptor (EGFR) is reportedly overexpressed in 15-20% of breast carcinomas.
  • This study assessed EGFR expression in breast carcinomas with squamous differentiation.
  • The immunohistochemical (IHC) expression of EGFR was evaluated in 39 breast carcinomas with squamous differentiation (30 pure squamous, 6 adenosquamous, 3 carcinosarcomas) by use of the pharmDx assay (clone 2-18C9, DakoCytomation).
  • Cases were considered positive if at least 10% of the cells showed 1+ positivity in the squamous component.
  • Squamous differentiation was confirmed with IHC for CK5-6 (clone D5/16B4, DakoCytomation).
  • As a control, a tissue microarray comprising 280 lymph node positive breast carcinomas was evaluated with the same EGFR assay.
  • At the time of initial diagnosis, 3 patients had distant metastasis.
  • Disease-free survival at 3 years was 70%.
  • EGFR-positive tumor cells (showing squamous morphology) were also found in 1 bone, 1 lung, and 8 of 11 lymph node metastases available for evaluation.
  • All 11 lymph nodes showed squamous differentiation.
  • No statistically significant differences in HER2 status, size, lymph node status and disease-free survival were observed between EGFR+ and EGFR- cases, but the number of EGFR-negative tumors was quite small.
  • Nine of 280 (3%) of lymph node-positive invasive carcinomas on the tissue microarray were EGFR+; review of the initial diagnostic slides failed to reveal squamous features in all but 1 of the 9 EGFR+ tumors.
  • Breast carcinomas with squamous differentiation are a distinct subgroup of breast tumors with a very high frequency of EGFR positivity.
  • Breast carcinomas of this type would be ideal candidates for a trial with EGFR inhibitors.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Squamous Cell / chemistry. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / chemistry. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Carcinoma, Adenosquamous / chemistry. Carcinoma, Adenosquamous / pathology. Carcinosarcoma / chemistry. Carcinosarcoma / pathology. Cell Differentiation. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / analysis. Lung Neoplasms / chemistry. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Surg Pathol. 2006 Jul;14(3):268; author reply 269 [16959717.001]
  • (PMID = 16273187.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


21. Akaeda T, Isaka K, Takayama M, Kakizaki D, Abe K: Myometrial invasion and cervical invasion by endometrial carcinoma: evaluation by CO2-volumetric interpolated breathhold examination (VIBE). J Magn Reson Imaging; 2005 Feb;21(2):166-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myometrial invasion and cervical invasion by endometrial carcinoma: evaluation by CO2-volumetric interpolated breathhold examination (VIBE).
  • PURPOSE: To assess myometrial invasion and cervical invasion by endometrial carcinoma, using CO2-volumetric interpolated breathhold examination (VIBE) enabling more precise evaluation of depth of tumor invasion.
  • MATERIALS AND METHODS: CO2-VIBE was performed in 21 cases of endometrial carcinoma (Stage Ia-IIb) prior to treatment.
  • The images were interpreted by performing multiplanar reconstruction (MPR), and the findings obtained from the images (degree of myometrial invasion and presence or absence of cervical invasion) were assessed in comparison with the histopathological diagnosis.
  • RESULTS: The sites of the endometrial carcinoma lesions were clearly visualized by the CO2-VIBE method.
  • Evaluation of the degree of myometrial invasion enabled a high correct diagnosis rate of 90.5%, and evaluation for the presence of cervical invasion also allowed a high correct diagnosis rate of 90.5%.
  • CONCLUSION: VIBE permits evaluation of any plane desired by means of thin slices, and it is a truly revolutionary method for preoperative evaluation of depth of invasion of endometrial carcinoma that enables highly accurate determination of the extent of lesion sites and degree of invasion before treatment.
  • [MeSH-major] Carbon Dioxide. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Image Enhancement / methods. Insufflation. Magnetic Resonance Imaging / methods. Myometrium / pathology. Uterine Cervical Neoplasms / diagnosis


22. Okabayashi K, Hasegawa H, Ishii Y, Endo T, Kitagawa Y: Adenosquamous carcinoma of the sigmoid colon treated by the less invasive procedures of endoscopy and laparoscopy: report of a case. Surg Today; 2009;39(11):994-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the sigmoid colon treated by the less invasive procedures of endoscopy and laparoscopy: report of a case.
  • A 51-year-old man demonstrated a positive finding for a fecal occult blood test during a screening examination.
  • Total colonoscopy was therefore performed, and a semi-pedunculated polyp was detected in the sigmoid colon.
  • Although this polyp was suspected of invading the submucosal layer, it was removed endoscopically because the preoperative diagnosis was well-differentiated adenocarcinoma.
  • The pathological findings revealed adenosquamous carcinoma that had invaded the submucosal layer with lymphatic invasion.
  • A laparoscopic bowel resection was then performed and a histopathological examination of the surgical specimen showed metastasis to two regional lymph nodes.
  • Adenosquamous carcinoma has been reported to be rare and to possess a highly metastatic potential.
  • It consists of both squamous cells and glandular cell components.
  • We report a case of adenosquamous carcinoma of the sigmoid colon treated by less invasive approaches consisting of an endoscopic mucosal resection and a subsequent laparoscopic colectomy.
  • [MeSH-major] Carcinoma, Adenosquamous / surgery. Colectomy / methods. Colon, Sigmoid / surgery. Colonoscopy / methods. Laparoscopy / methods. Sigmoid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):258-63 [10211505.001]
  • [Cites] Int J Colorectal Dis. 1992 Sep;7(3):144-7 [1402312.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1265-8 [8918436.001]
  • [Cites] Surg Today. 2009;39(1):83-7 [19132477.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):323-6 [3282843.001]
  • [Cites] J Natl Cancer Inst. 1981 Jul;67(1):149-54 [6942185.001]
  • [Cites] Dis Colon Rectum. 1989 Aug;32(8):716-21 [2666053.001]
  • (PMID = 19882324.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. de Jong WK, Schaapveld M, Blaauwgeers JL, Groen HJ: Pulmonary tumours in the Netherlands: focus on temporal trends in histology and stage and on rare tumours. Thorax; 2008 Dec;63(12):1096-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on ICD-O morphology codes, five major subgroups were constructed: squamous carcinoma (SC), adenocarcinoma (AC), large cell (undifferentiated) carcinoma (LC), small cell lung cancer (SCLC) and other (including uncommon tumours).
  • Since 1996, a stage shift was observed with fewer patients in stage I and more patients in stage IV at diagnosis.
  • In SC, fewer patients presented with stage IV disease than in AC and LC (25% vs 44% and 49% in 2003, respectively).
  • The incidence of adenosquamous carcinoma decreased from 0.6 to 0.29/100 000 (p<0.001).
  • The incidence of carcinoid tumours, sarcomatoid carcinomas and primary pulmonary sarcomas remained stable (0.44, 0.17 and 0.08/100 000, respectively).
  • More patients presented with stage IV disease.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Carcinoma, Large Cell / epidemiology. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Netherlands / epidemiology. Small Cell Lung Carcinoma / epidemiology. Small Cell Lung Carcinoma / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18678702.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


24. Rodríguez-Sastre MA, González-Maya L, Delgado R, Lizano M, Tsubaki G, Mohar A, García-Carrancá A: Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix. Gynecol Oncol; 2005 May;97(2):330-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We performed an immunochemical staining analysis of the cellular distribution of beta-catenin and E-cadherin proteins in biopsy samples from 20 normal exocervical squamous epithelium, 43 premalignant lesions, and a large series of 126 invasive tumors of different histologic types that included 68 squamous carcinomas, 31 adenosquamous carcinomas, and 27 adenocarcinomas.
  • Similarly, we found that E-cadherin exhibit a significant abnormal distribution in the cytoplasm of 58% of premalignant lesions (P < 0.05) and in more than 71% of squamous carcinoma and adenosquamous carcinoma when compared with normal tissue (P < 0.05).
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervix Uteri / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. beta Catenin


25. Pinheiro C, Longatto-Filho A, Ferreira L, Pereira SM, Etlinger D, Moreira MA, Jubé LF, Queiroz GS, Schmitt F, Baltazar F: Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int J Gynecol Pathol; 2008 Oct;27(4):568-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma.
  • The series analyzed included 29 chronic cervicitis, 30 low-grade squamous intraepithelial lesions, 32 high-grade squamous intraepithelial lesions, 49 squamous cell carcinomas, 51 adenocarcinomas, and 30 adenosquamous carcinomas of the uterine cervix.
  • We found a significant increase in MCT expression from preinvasive to invasive squamous lesions and from normal glandular epithelium to adenocarcinomas.
  • This is the first study evaluating the significance of MCT expression in lesions of the uterine cervix, including invasive carcinomas, and the results found herein led us to believe that these membrane proteins are involved in the progression to invasiveness in uterine cervix carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Monocarboxylic Acid Transporters / biosynthesis. Muscle Proteins / biosynthesis. Symporters / biosynthesis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Disease Progression. Female. Humans. Immunohistochemistry. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753962.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Monocarboxylic Acid Transporters; 0 / Muscle Proteins; 0 / SLC16A4 protein, human; 0 / Symporters; 0 / monocarboxylate transport protein 1
  •  go-up   go-down


26. Robledo-Ogazón F, Vargas-Rivas A, Hernández-Ramírez DA, Castellanos-Juárez JC: [Congenital diaphragmatic adult hernia. Case report]. Cir Cir; 2008 Jan-Feb;76(1):61-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hernia diafragmática congénita en el adulto. Informe de un caso.
  • Diagnosis is incidental or when it becomes symptomatic.
  • Our objective was to offer the general surgeon a differential diagnosis for presence of noncardiac thoracic pain in the adult.
  • It is important that the surgeon establishes an etiological diagnosis in order to offer appropriate treatment.
  • CONCLUSIONS: Congenital diaphragmatic hernia in the adult is rarely suspected in the differential diagnosis of noncardiac thoracic pain.
  • The surgeon must keep this in mind, especially in patients of advanced age, even when cardiac and/or gastrointestinal diagnosis is confirmed.
  • [MeSH-minor] Age of Onset. Aged. Carcinoma, Adenosquamous / complications. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Cholecystectomy. Cholelithiasis / complications. Cholelithiasis / surgery. Cough / etiology. Diagnostic Errors. Dyspepsia / diagnosis. Female. Gallbladder Neoplasms / complications. Gallbladder Neoplasms / radiography. Gallbladder Neoplasms / surgery. Gastroesophageal Reflux / etiology. Heart Diseases / diagnosis. Hernia, Diaphragmatic / complications. Hernia, Diaphragmatic / diagnosis. Hernia, Diaphragmatic / epidemiology. Humans. Incidental Findings. Lung Diseases / diagnosis. Tomography, X-Ray Computed


27. Sun Y, Lin H, Zhu Y, Feng J, Chen Z, Li G, Zhang X, Zhang Z, Tang J, Shi M, Hao X, Han H: [A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi; 2006 Jun 20;9(3):254-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients].
  • The aim of this study is to observe the clinical anticancer effect of Rg3 in combination with chemotherapy regimen NP (vinorelbine+cisplatin) in advanced non-small cell lung cancer (NSCLC).
  • Types of pathology: adenocarcinoma, 71; squamous cell carcinoma, 29; adenosquamous carcinoma, 8; others, 7.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21172156.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Niwa Y, Matsuo K, Ito H, Hirose K, Tajima K, Nakanishi T, Nawa A, Kuzuya K, Tamakoshi A, Hamajima N: Association of XRCC1 Arg399Gln and OGG1 Ser326Cys polymorphisms with the risk of cervical cancer in Japanese subjects. Gynecol Oncol; 2005 Oct;99(1):43-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The cases comprised 131 cervical cancer patients: 87 cases with squamous cell carcinoma (SCC) and 44 with adenocarcinoma (ADC) or adenosquamous carcinoma (ADSC).
  • RESULTS: The frequency of the XRCC1 399GlnGln genotype was higher in individuals with adenocarcinoma/adenosquamous carcinoma than in the healthy controls (OR = 2.98, 95% CI = 1.11-8.01, P = 0.030).
  • In stratification analysis, significant elevated risk of adenocarcinoma/adenosquamous carcinoma was associated with the XRCC1 399GlnGln genotype among nonsmokers (OR = 3.85, 95% CI = 1.28-11.59, P = 0.017), but not among smokers.
  • CONCLUSION: This is the first report that the XRCC1 Arg399Gln polymorphism might be important in relation to the risk of adenocarcinoma/adenosquamous carcinoma of the cervix.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Alleles. Carcinoma, Adenosquamous / enzymology. Carcinoma, Adenosquamous / genetics. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / genetics. Case-Control Studies. Female. Genetic Predisposition to Disease. Humans. Japan. Middle Aged. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990162.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human
  •  go-up   go-down


29. Ren G, Yu G, Liu LW, Ma L: [Expressions of Ep-CAM and cyclin D1 and their clinical significance in gallbladder carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Nov;31(11):841-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of Ep-CAM and cyclin D1 and their clinical significance in gallbladder carcinoma].
  • OBJECTIVE: To investigate the expressions of Ep-CAM and cyclin D1 and their correlation with the clinicopathological factors and prognosis in gallbladder carcinoma.
  • METHODS: Ep-CAM and cyclin D1 expressions were detected by PV6000 immunohistochemical staining in 60 gallbladder carcinoma and 15 para-cancerous mucosa specimens.
  • CONCLUSION: Ep-CAM or cyclin D1 expression is a unfavorable prognostic factor in gallbladder carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Cell Adhesion Molecules / metabolism. Cyclin D1 / metabolism. Gallbladder Neoplasms / metabolism
  • [MeSH-minor] Aged. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137349.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CCND1 protein, human; 0 / Cell Adhesion Molecules; 0 / tumor-associated antigen GA733; 136601-57-5 / Cyclin D1
  •  go-up   go-down


30. Endo K, Kohnoe S, Okamura T, Haraguchi M, Adachi E, Toh Y, Baba H, Maehara Y: Gastric adenosquamous carcinoma producing granulocyte-colony stimulating factor. Gastric Cancer; 2005;8(3):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenosquamous carcinoma producing granulocyte-colony stimulating factor.
  • We report a case of adenosquamous carcinoma of the stomach that produced granulocyte-colony stimulating factor (G-CSF).
  • The patient, who had an admission diagnosis of advanced gastric cancer, had marked leukocytosis without evidence of infection.
  • The resected stomach tumor was histologically diagnosed as adenosquamous carcinoma; positive expression of G-CSF by tumor cells was shown with immunohistochemical detection, which confirmed the preoperative diagnosis.
  • Recurrent disease in the liver and lymph nodes, accompanied by leukocytosis and re-elevation of serum G-CSF, developed just 3 months after the curative gastrectomy and adjuvant chemotherapy.
  • All of the recurrent disease was resected, restoring normal levels of serum G-CSF.
  • [MeSH-major] Carcinoma, Adenosquamous / metabolism. Granulocyte Colony-Stimulating Factor / metabolism. Leukocytosis / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 May 10;109(6):826-32 [15027115.001]
  • [Cites] J Biol Chem. 1979 Jul 25;254(14):6226-8 [312800.001]
  • [Cites] Scand J Haematol. 1982 May;28(5):417-24 [6981836.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3438-43 [7542171.001]
  • [Cites] Gut. 2000 Mar;46(3):432-4 [10673310.001]
  • [Cites] J Natl Cancer Inst. 1982 Dec;69(6):1235-43 [6982994.001]
  • [Cites] Blood. 1985 Aug;66(2):407-15 [2990610.001]
  • [Cites] Cancer. 1986 Jan 15;57(2):333-9 [3942965.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Cancer. 1965 Feb;18:181-92 [14254074.001]
  • [Cites] Hum Pathol. 1989 Sep;20(9):878-85 [2789172.001]
  • [Cites] Jpn J Cancer Res. 1986 Feb;77(2):168-76 [3082828.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9323-6 [2480598.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1423-33 [11583970.001]
  • (PMID = 16086120.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


31. Takahashi T, Yamamoto N, Nukiwa T, Mori K, Tsuboi M, Horai T, Masuda N, Eguchi K, Mitsudomi T, Yokota S, Segawa Y, Ichinose Y, Fukuoka M, Saijo N: Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res; 2010 Feb;30(2):557-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
  • The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent advanced non-small cell lung cancer (NSCLC).
  • RESULTS: Of the 46 patients, 13 were assessed to have a partial response and 9 had stable disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Erlotinib Hydrochloride. Female. Humans. Japan. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome. Young Adult


32. Massard G, Ducrocq X, Kochetkova EA, Porhanov VA, Riquet M: Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study. Eur J Cardiothorac Surg; 2006 Jul;30(1):164-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: During a 4-month period, 208 consecutive patients (172 men, 36 women) without bulky disease underwent resection for primary lung cancer in three centers.
  • There were 108 squamous cell carcinomas, 621 adenocarcinomas, 18 bronchoalveolar carcinomas, 8 large cell carcinomas, 4 adenosquamous carcinomas and 8 neuroendocrine carcinomas.
  • N2 disease concerned a single node in 16, a single node station in 19, and multiple levels in 25.
  • Sampling adequately recognized N2 disease in 31 patients (52%).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Lymph Node Excision / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2007 Jan;31(1):142-3; author reply 143-4 [17092737.001]
  • (PMID = 16725340.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


33. Chen JR, Lee YJ, Chen T, Wang KL, Dang CW, Chang SC, Liu HF, Yang YC: MHC class I chain-related gene A (MICA) polymorphism and the different histological types of cervical cancer. Neoplasma; 2005;52(5):369-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • About 70-80% are squamous cell carcinoma; the remainder are composed of various types of adenocarcinoma, adenosquamous carcinoma and undifferentiated carcinoma.
  • We analyzed the MICA polymorphism in 110 cervical cancer cases (88 squamous cell carcinoma, 12 adenocarcinoma and 10 adenosquamous carcinoma) and 82 randomly selected unrelated controls from 1994 to 2000 in the Mackay Memorial Hospital, Taipei, Taiwan.
  • DNA was extracted part from leukocytes of peripheral blood, part from tumor tissue and 5 polymorphic microsatellite alleles (A4,A5,A5.1,A6,A9) of MICA were identified by a polymerase chain reaction-based (PCR) technique using ABI Prism 377-18 DNA sequencer (Applied Biosystems, Foster City, CA, USA).
  • After dividing the cervical cancer patients into 3 major histological types (squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma), the result was still the same (p=0.598, 0.172 and 0.617) in our study.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Squamous Cell / genetics. Histocompatibility Antigens Class I / genetics. Polymorphism, Genetic. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Genetic Predisposition to Disease. Humans. Microsatellite Repeats. Polymerase Chain Reaction. Taiwan / epidemiology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16151576.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class I; 0 / MHC class I-related chain A
  •  go-up   go-down


34. Kuwabara Y, Susumu N, Banno K, Hirao T, Kawaguchi M, Yamagami W, Suzuki N, Aoki D, Nozawa S: Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan. Jpn J Clin Oncol; 2005 Jan;35(1):23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan.
  • BACKGROUND: It has been reported that prognosis is less favorable in poorly (G3) differentiated endometrioid adenocarcinoma than in well (G1) or moderately (G2) differentiated endometrioid adenocarcinoma.
  • The goal of this study is therefore to analyze the prognosis of G3 endometrioid adenocarcinoma and various factors that may predict a favorable prognosis.
  • METHOD: This study included 699 Japanese cases of endometrioid adenocarcinoma at the International Federation of Gynaecology and Obstetrics (FIGO) surgical stages I-IV (including 74 G3 cases).
  • We investigated the G1-G3 survival rates of endometrioid adenocarcinoma cases and the G2 and G3 disease-free periods.
  • We also examined the clinicopathological characteristics of G3 endometrioid adenocarcinoma.
  • The absence of adnexal metastasis and low pre-surgery CA19-9 values may suggest a relatively favorable prognosis in G3 endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Cell Cycle. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / secondary. Prognosis. Survival Rate. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15681600.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Chao A, Wang TH, Lee YS, Hsueh S, Chao AS, Chang TC, Kung WH, Huang SL, Chao FY, Wei ML, Lai CH: Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer; 2006 Jul 1;119(1):91-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression.
  • In an attempt to understand the molecular mechanisms for the different clinical features between adenocarcinoma/adenosquamous carcinoma (AC/ASC) and squamous carcinoma (SC) of the uterine cervix, we analyzed gene expression profiles of different histological subtypes of cervical cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Microarray Analysis. Uterine Cervical Neoplasms / genetics


36. Neumann G, Rasmussen KL, Petersen LK: Cervical adenosquamous carcinoma: tumor implantation in an episiotomy scar. Obstet Gynecol; 2007 Aug;110(2 Pt 2):467-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenosquamous carcinoma: tumor implantation in an episiotomy scar.
  • BACKGROUND: We report a rare case of a cervical adenosquamous carcinoma, initially diagnosed during delivery, with subsequent implantation in the episiotomy scar 5 weeks postpartum.
  • CASE: A 35-year-old woman with cervical adenosquamous carcinoma diagnosed during delivery was treated with radical abdominal hysterectomy with bilateral pelvic lymphadenectomy.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Cicatrix / pathology. Episiotomy. Pregnancy Complications, Neoplastic / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Hysterectomy. Lymph Node Excision. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local. Pregnancy. Puerperal Disorders / diagnosis. Puerperal Disorders / pathology. Puerperal Disorders / therapy


37. Kausar F, Davis MP: Ketorolac in neuropathic pain. J Pain Symptom Manage; 2006 Sep;32(3):202-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Breast Neoplasms / complications. Breast Neoplasms / therapy. Carcinoma, Adenosquamous / complications. Carcinoma, Adenosquamous / therapy. Female. Humans. Lymphatic Metastasis. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939842.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; YZI5105V0L / Ketorolac
  •  go-up   go-down


38. Lizano M, De la Cruz-Hernández E, Carrillo-García A, García-Carrancá A, Ponce de Leon-Rosales S, Dueñas-González A, Hernández-Hernández DM, Mohar A: Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population. Gynecol Oncol; 2006 Aug;102(2):230-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Distribution of HPV variants was correlated with the cytological findings and tumor cell types using contingency tables.
  • From a total of 135 invasive carcinomas, 78.5% were squamous (106 cases); 6.6% adenocarcinoma (9 cases); 9.6% adenosquamous (ADSC) (13 cases); and 5.1% were undifferentiated carcinoma (7 cases).
  • In invasive cancer, this variant was found only in squamous tumors.


39. Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Small W, Greven K: Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The overall and disease-free survival rates were determined.
  • The estimated 2-year disease-free survival and overall survival rate was 69% and 83%, respectively.
  • Of the 78 patients, 24 had treatment failure: 3 with persistent local disease, 9 local only, 2 regional, 4 distant, 1 regional and distant, 1 local and distant, and 2 with local, regional, and distant disease, and 1 had died of cervical cancer without a reported site of first failure and 1 without evidence of disease.
  • CONCLUSION: At 2 years, the estimated disease-free survival and overall survival rate for patients with advanced cervical cancer who underwent a combination of chemoradiotherapy and celecoxib treatment was 69% and 83%, respectively.
  • Recurrent disease developed in 24 patients, and, of those patients, 18 had a component of locoregional failure as a site of first failure.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482376.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633; United States / NCI NIH HHS / CA / R01 CA106633-01; United States / NCI NIH HHS / CA / CA106633-02; United States / NCI NIH HHS / CA / R01 CA106633-02; United States / NCI NIH HHS / CA / CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633-04; United States / NCI NIH HHS / CA / CA106633-04; United States / NCI NIH HHS / CA / CA106633-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


40. Liao QH: [A clinicopathological study of 16 autopsy cases of anthracosilicosis with lung cancer]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2005 Oct;23(5):340-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 16 cases of lung cancer, there were 5 cases of squamous cell carcinoma, and 5 cases of small cell undifferentiated carcinoma, 3 cases of bronchioloalveolar carcinoma, 2 cases of adenocarcinoma and 1 case of adenosquamous carcinoma.


41. Cunha IW, Guimaraes GC, Soares F, Velazquez E, Torres JJ, Chaux A, Ayala G, Cubilla AL: Pseudoglandular (adenoid, acantholytic) penile squamous cell carcinoma: a clinicopathologic and outcome study of 7 patients. Am J Surg Pathol; 2009 Apr;33(4):551-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoglandular (adenoid, acantholytic) penile squamous cell carcinoma: a clinicopathologic and outcome study of 7 patients.
  • Almost half of penile squamous cell carcinomas (SCCs) are of the usual type but there is a variegated spectrum of morphologically distinctive subtypes.
  • Microscopically, tumors were SCC with acantholytic areas ranging from solid nests with early necrosis or empty pseudoluminal spaces lined by 1 layer of squamous cells or cylindrical cells strikingly simulating glands.
  • The differential diagnosis was with gland forming penile tumors (surface adenosquamous, mucoepidermoid, and urethral adenocarcinomas) and the angiosarcomatoid variant of sarcomatoid carcinomas.
  • There was regional nodal metastasis in 3 patients, 2 of which died from disease.
  • The other 5 were either alive with no evidence of disease (12 and 21 y after diagnosis) or died from causes other than penile cancer (3, 4, and 7 y after diagnosis).
  • [MeSH-major] Acantholysis / pathology. Carcinoma, Squamous Cell / pathology. Penile Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2009 Sep;33(9):1421-2 [19609203.001]
  • (PMID = 19033863.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Teramoto N, Nishimura R, Saeki T, Nogawa T, Hiura M: Adenoid basal carcinoma of the uterine cervix: report of two cases with reference to adenosquamous carcinoma. Pathol Int; 2005 Jul;55(7):445-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid basal carcinoma of the uterine cervix: report of two cases with reference to adenosquamous carcinoma.
  • Adenoid basal carcinoma (ABC) of the uterine cervix is a rare neoplasm with excellent prognosis.
  • Differential diagnosis between ABC and an ABC-like lesion of adenosquamous cell carcinoma (ASC) of the cervix is important due to their contrasting prognosis.
  • The two ABC were incidentally found in the uterine cervix of 69-year-old and 59-year-old Japanese women due to cervical intraepithelial neoplasia grade 3 and to squamous cell carcinoma, respectively.
  • An ABC-like lesion was defined as basaloid cell nests simulating ABC, but with some features indicating malignant potential.
  • However, the differential diagnosis was sometimes difficult because two of seven ABC-like lesions were originally diagnosed as ABC.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Basal Cell / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratin-8. Keratins / analysis. Ki-67 Antigen / analysis. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982222.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / KRT8 protein, human; 0 / Keratin-7; 0 / Keratin-8; 0 / Ki-67 Antigen; 68238-35-7 / Keratins
  •  go-up   go-down


43. Ereno C, López JI, Bilbao FJ: The biphasic pattern of laryngeal and hypopharyngeal adenosquamous carcinoma is retained in lymph node metastases. Histopathology; 2005 Jun;46(6):715-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biphasic pattern of laryngeal and hypopharyngeal adenosquamous carcinoma is retained in lymph node metastases.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Hypopharyngeal Neoplasms / pathology. Laryngeal Neoplasms / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Fatal Outcome. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Histopathology. 2004 Jun;44(6):570-9 [15186272.001]
  • (PMID = 15910609.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


44. Milam MR, Abaid L, dos Reis R, Frumovitz M, Gehrig PA, Livasy C, Broaddus RR, Ramirez PT: Microscopic evaluation of lymph-node-bearing tissue in early-stage cervical cancer: a dual-institution review. Ann Surg Oncol; 2010 Apr;17(4):1106-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Uterine Cervical Neoplasms / pathology


45. Wei WZ, Yu JP, Li J, Liu CS, Zheng XH: Evaluation of contrast-enhanced helical hydro-CT in staging gastric cancer. World J Gastroenterol; 2005 Aug 7;11(29):4592-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Papillary / radiography. Neoplasm Staging / methods. Stomach Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Contrast Media. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052695.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC4398715
  •  go-up   go-down


46. Löhe F, Meimarakis G, Schauer C, Angele M, Jauch KW, Schauer RJ: The time of diagnosis impacts surgical management but not the outcome of patients with gallbladder carcinoma. Eur J Med Res; 2009 Aug 12;14(8):345-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The time of diagnosis impacts surgical management but not the outcome of patients with gallbladder carcinoma.
  • Therefore, the time of diagnosis may strongly influence the surgical management of GBC and the prognosis of the patients.
  • METHODS: Records and follow- up of 152 patients with gallbladder carcinoma who underwent surgery between 1980 and 2004 were examined according to the time of diagnosis, TNM staging system, surgical procedures, morbidity and predictors of survival.
  • There were 76 patients with preoperative diagnosis of GBC (50%; group1), 44 patients with intraoperative diagnosis (29%; group 2) and 32 patients (21%; group 3) with postoperatively incidental finding of GBC.
  • Tumor stage, in particular the nodal status and radicality of the procedure, but not the time of diagnosis were the most powerful predictors of outcome.
  • Although the time of diagnosis of GBC causes significant changes of the intended procedures during and after surgery, it has no influence on the prognosis provided that radical (R0) resection was accomplished.
  • [MeSH-major] Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Cholecystectomy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Oct;232(4):557-69 [10998654.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):806-16 [18985272.001]
  • [Cites] Langenbecks Arch Surg. 2000 Dec;385(8):501-8 [11201005.001]
  • [Cites] Am Surg. 2001 Nov;67(11):1041-7 [11730220.001]
  • [Cites] World J Surg. 2002 Jul;26(7):867-71 [11960212.001]
  • [Cites] Zentralbl Chir. 2003 Apr;128(4):309-12 [12700988.001]
  • [Cites] Cancer. 1976 Jan;37(1):141-8 [1247951.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):237-41 [2302063.001]
  • [Cites] Am J Surg. 1992 Feb;163(2):239-45 [1739180.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):326-31 [1558412.001]
  • [Cites] Ann Surg. 1994 Mar;219(3):275-80 [8147608.001]
  • [Cites] Surgery. 1994 Jun;115(6):751-6 [7910985.001]
  • [Cites] Br J Surg. 1996 Apr;83(4):478-81 [8665234.001]
  • [Cites] Surgery. 1996 Nov;120(5):816-21 [8909516.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):639-46 [8916879.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):892-9 [9041150.001]
  • [Cites] Br J Surg. 1997 Feb;84(2):200-4 [9052434.001]
  • [Cites] Eur J Surg. 1997 Jun;163(6):419-26 [9231853.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1529-32 [10430289.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1557-60 [10430294.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2114-21 [10521952.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2122-7 [10521953.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2138-43 [10521956.001]
  • [Cites] World J Surg. 2005 Sep;29(9):1106-9, discussion 1110 [16086210.001]
  • [Cites] J Surg Oncol. 2006 Jun 15;93(8):670-81 [16724356.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):524-35 [16998361.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):833-40 [17103074.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(4):358-65 [17653633.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1188-93 [17712596.001]
  • [Cites] Surg Endosc. 2007 Sep;21(9):1582-7 [17479340.001]
  • [Cites] Chirurg. 2007 Sep;78(9):802-9 [17680231.001]
  • [Cites] Eur J Surg Oncol. 2008 Mar;34(3):306-12 [17964753.001]
  • [Cites] Surgeon. 2008 Apr;6(2):101-10 [18488776.001]
  • [Cites] AJR Am J Roentgenol. 2008 Sep;191(3):765-71 [18716107.001]
  • [Cites] Surg Endosc. 2008 Nov;22(11):2462-5 [18247090.001]
  • [Cites] Ann Surg. 2008 Nov;248(5):807-14 [18948808.001]
  • [Cites] Langenbecks Arch Surg. 2000 Dec;385(8):495-500 [11201004.001]
  • (PMID = 19666394.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3352165
  •  go-up   go-down


47. Hammouda D, Muñoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, Djedeat B, Fontanière B, Snijders P, Meijer C, Franceschi S: Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors. Int J Cancer; 2005 Jan 20;113(3):483-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors.
  • A total of 198 cervical carcinoma (CC) cases (including 15 adeno- and adenosquamous carcinomas) and 202 age-matched control women were included.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Adenosquamous. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Uterine Cervical Neoplasms

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455386.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


48. Imadome K, Iwakawa M, Nakawatari M, Fujita H, Kato S, Ohno T, Nakamura E, Ohkubo Y, Tamaki T, Kiyohara H, Imai T: Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity. Cancer Biol Ther; 2010 Nov 15;10(10):1019-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity.
  • Adenosquamous carcinoma (ASC) is a relatively uncommon histological subtype of cervical cancer (CC).
  • A point of controversy is the relative prognosis of ASC compared to squamous cell carcinoma (SCC).
  • All adenocarcinoma (AC) patients were classified into one cluster, and most SCC patients fell into the other cluster.
  • In addition, the inhibition of EpCAM expression using siRNA significantly increased radiation-induced cell death in the cervical cell line, ME-180.
  • [MeSH-major] Adenocarcinoma / classification. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Adenosquamous / classification. Carcinoma, Squamous Cell / classification. Cell Adhesion Molecules / metabolism. Radiation Tolerance / genetics. Uterine Cervical Neoplasms / classification


49. Ko CJ, Leffell DJ, McNiff JM: Adenosquamous carcinoma: a report of nine cases with p63 and cytokeratin 5/6 staining. J Cutan Pathol; 2009 Apr;36(4):448-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma: a report of nine cases with p63 and cytokeratin 5/6 staining.
  • Adenosquamous carcinoma, a rare tumor of the skin with few reported cases in the literature, has not been studied with p63, cytokeratin 5/6 and cytokeratin 7.
  • Histologically, the tumors showed superficial, atypical islands of keratinocytes in close association with islands displaying glandular differentiation.
  • Clinically, lesions favored the head and trunk, and a subset of cases showed aggressive behavior.
  • Recognition of adenosquamous carcinoma is important for appropriate therapy, and stains for p63 and cytokeratin 5/6 may be helpful in ruling out metastatic adenocarcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Keratin-5 / biosynthesis. Keratin-6 / biosynthesis. Membrane Proteins / biosynthesis. Skin Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Keratin-7 / biosynthesis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278431.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Keratin-7; 0 / Membrane Proteins
  •  go-up   go-down


50. Ak I, Sivrikoz MC, Entok E, Vardareli E: Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. Eur J Cardiothorac Surg; 2010 Apr;37(4):792-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
  • The objective of our study was to compare the sensibility of the 2-deoxy-2-[18F] fluoro-d-glucose positron emission tomography/computed tomography (F-18 FDG PET/CT) for the detection of bone metastasis in patients with non-small-cell lung cancer (NSCLC) whose technetium 99m methylenediphosphonate (Tc-99m MDP) bone scans were absolutely normal.
  • RESULTS: Nine patients had squamous cell carcinoma, six had adenocarcinoma, three had large cell carcinoma and one had adenosquamous cell carcinoma.
  • Tc-99m MDP bone scan that did not reveal bony abnormalities or radiotracer uptake was characteristic of benign disease (defined as absolutely normal) in these patients.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20015657.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


51. Lüttges J, Klöppel G: [Pancreatic ductal adenocarcinoma and its precursors]. Pathologe; 2005 Feb;26(1):12-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic ductal adenocarcinoma and its precursors].
  • Pancreatic ductal adenocarcinoma is the most frequent malignant pancreatic tumor.
  • Its morphological characteristics are: preferential localization in the head of the pancreas, ductal-glandular tumor structures combined with marked desmoplasia and CEA and MUC1 positivity.
  • Variants of this carcinoma include adenosquamous carcinomas, undifferentiated pleomorphic carcinomas and mixed ductal-endocrine tumors.
  • With the definition of ductal lesions as pancreatic intraepithelial neoplasia, a progression model for pancreatic ductal carcinoma has been developed and corresponding gene alterations have been detected.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Precancerous Conditions / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Gastroenterol Rep. 2004 Apr;6(2):111-8 [15191688.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;880:210-8 [10415866.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 [12569143.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):508-17 [12942322.001]
  • [Cites] Semin Oncol. 1996 Apr;23(2):241-50 [8623060.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):83-92 [10880379.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • [Cites] Gastroenterology. 1954 Nov;27(5):629-40 [13210601.001]
  • [Cites] World J Surg. 2000 May;24(5):595-601; discussion 601-2 [10787083.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Pancreatology. 2001;1(6):571-5 [12120238.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):173-82 [14692038.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2123-33 [10854233.001]
  • [Cites] J Pathol. 2003 Sep;201(1):63-74 [12950018.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Dig Surg. 1999;16(4):291-6 [10449973.001]
  • [Cites] Pathology. 2003 Feb;35(1):14-24 [12701679.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):165-81 [9443994.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • [Cites] Virchows Arch. 1998 Sep;433(3):237-42 [9769127.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • (PMID = 15630571.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mucin-1
  •  go-up   go-down


52. Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, Hida T, Mitsudomi T, Yatabe Y: Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res; 2008 Oct 1;14(19):6092-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor mutations in small cell lung cancer.
  • PURPOSE: The vast majority of epidermal growth factor receptor (EGFR) mutations occur in lung adenocarcinoma, and even rare cases of other subtypes with this mutation, such as adenosquamous cell carcinoma, are associated with adenocarcinoma histology.
  • According to this adenocarcinoma-specific nature of EGFR mutation, analysis of EGFR mutations with small cell lung cancers (SCLC) may provide a clue to its histogenesis.
  • Notably, in three tumors of the combined SCLC subtype, both components of adenocarcinoma and SCLC harbored an EGFR mutation, whereas gene amplification was detected only in the adenocarcinoma component.
  • CONCLUSIONS: Although EGFR mutations are rare in SCLC, a combined subtype of SCLC with adenocarcinoma in light smokers may have a chance of harboring EGFR mutations.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, erbB-1. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / physiology. Small Cell Lung Carcinoma / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829487.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


53. Mori T, Nomori H, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, Yamashita Y: Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol; 2008 Apr;3(4):358-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography.
  • INTRODUCTION: Recent developments of diffusion-weighted magnetic resonance imaging (DWI) make it possible to image malignant tumors to provide tissue contrast based on difference in the diffusion of water molecules among tissues, which can be measured by apparent diffusion coefficient (ADC) value.
  • The aim of this study is to examine the usefulness of DWI for benign/malignant discrimination of pulmonary nodules/masses compared with F-fluorodeoxyglucose (FDG) positron emission tomography (PET).
  • RESULTS: The receiver operating characteristics curve showed cutoff values of the ADC-min and the SUV-CR for benign/malignant discrimination to be 1.1 x 10 mm/s and 0.37, respectively.
  • CONCLUSIONS: DWI may be able to be used in place of FDG-PET to distinguish malignant from benign pulmonary nodules/masses with fewer false-positive results compared with FDG-PET.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Lung Neoplasms / diagnosis. Positron-Emission Tomography / methods. Solitary Pulmonary Nodule / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diagnostic Imaging. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Prognosis. Prospective Studies. ROC Curve. Sensitivity and Specificity. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379353.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


54. Piantedosi FV, Caputo F, Mazzarella G, Gilli M, Pontillo A, D'Agostino D, Campbell S, Marsico SA, Bianco A: Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study. Cancer Chemother Pharmacol; 2008 Apr;61(5):803-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
  • To investigate the activity/toxicity of T 175 mg/m2 on day 1, I 3 g/m2 on day 1 (with Mesna uroprotection) and G 1,000 mg/m2 on day 1-8, every 3 weeks in the treatment of advanced/metastatic NSCLC, 46 patients (38 male, 8 female) with NSCLC were enrolled: mean age 58 (range 33-70); Stage IIIB/IV=15/31; ECOG PS 0-1/2=31/15; HISTOLOGY: adenocarcinoma=20, squamous=14, large cell=3, NSCLC=8, adenosquamous=1.
  • In intent-to-treat analysis, partial response was achieved in 17 patients (36.95%), stable disease and progressive disease was detected in 16 (34.78%) and 10 (21.73%) patients, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Disease-Free Survival. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Paclitaxel / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639396.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


55. Trikudanathan G, Dasanu CA: Adenosquamous carcinoma of the pancreas: a distinct clinicopathologic entity. South Med J; 2010 Sep;103(9):903-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas: a distinct clinicopathologic entity.
  • Among exocrine pancreatic tumors, adenosquamous carcinoma (ASC) is a rare, aggressive subtype with a worse prognosis and a higher potential for metastases compared to its more conventional glandular counterpart, adenocarcinoma.
  • The disease distribution shows an approximately 1:1 male/female ratio and a median survival of circa five months.
  • Humoral hypercalcemia of malignancy has also been described with ASC of the pancreas, likely as a result of PTHrP production by the squamous component of the tumor.
  • Similar to the therapeutics of pancreatic adenocarcinoma, adjuvant chemotherapy or chemoradiotherapy is currently indicated for resectable ASC of the pancreas, while gemcitabine or gemcitabine combinations are used for a more advanced disease.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Abdominal Pain / etiology. Biomarkers, Tumor. Chemotherapy, Adjuvant. Diagnostic Imaging. Genetic Predisposition to Disease. Humans. Jaundice / etiology. Mutation. Necrosis. Palliative Care. Pancreas / pathology. Pancreatectomy. Risk Factors. Survival Analysis. Weight Loss

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697320.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 43
  •  go-up   go-down


56. Ramirez PT, Slomovitz BM, Soliman PT, Coleman RL, Levenback C: Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol; 2006 Aug;102(2):252-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data collected included age, body mass index, stage, histopathologic subtype, tumor grade, estimated blood loss, perioperative blood transfusions, number and status of lymph nodes obtained, status of surgical margins, length of hospital stay, time to resumption of normal bladder function, intraoperative and postoperative complications, and disease-free interval.
  • Among those with cervix cancer, 12 had adenocarcinoma, 4 squamous cell carcinoma, and 2 adenosquamous carcinoma.
  • One patient had nodal disease.
  • The surgical margins were free of disease in all cases.
  • There were 2 long-term complications--vaginal eviscerations and a lymphocyst.
  • All patients remain free of disease at the time of this report.
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2007 Feb;104(2):501; author reply 501-3 [17157902.001]
  • (PMID = 16472844.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Voong KR, Davison J, Pawlik TM, Uy MO, Hsu CC, Winter J, Hruban RH, Laheru D, Rudra S, Swartz MJ, Nathan H, Edil BH, Schulick R, Cameron JL, Wolfgang CL, Herman JM: Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum Pathol; 2010 Jan;41(1):113-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients.
  • Pancreatic adenosquamous carcinoma is a rare morphological variant of pancreatic adenocarcinoma with an especially poor prognosis.
  • The purpose of this study is to identify clinicopathologic features associated with prognosis, assess whether the percentage of squamous differentiation in pancreatic adenosquamous carcinoma is associated with an inferior prognosis, and examine the impact of adjuvant chemoradiation therapy on overall survival.
  • Forty-five (1.2%) of 3651 patients who underwent pancreatic resection at the Johns Hopkins Hospital, Baltimore, MD, between 1986 and 2007 were identified with adenocarcinoma of the pancreas with any squamous differentiation.
  • Seventy-six percent of carcinomas were node positive, 37% were margin-positive resections, and 68% had 30% or more squamous differentiation.
  • Median overall survival of the pancreatic adenosquamous carcinoma cohort was 10.9 months (range, 2.1-140.6 months; 95% confidence interval, 8.2-12.5 months).
  • Adjuvant chemoradiation therapy was associated with superior overall survival in patients with pancreatic adenosquamous carcinoma (P = .005).
  • The proportion of squamous differentiation was not associated with median overall survival (< 30% versus > or = 30%, P = .82).
  • Survival after pancreatic resection of pancreatic adenosquamous carcinoma is poor.
  • The proportion of squamous differentiation in resected pancreatic adenosquamous carcinoma specimens does not appear to impact overall survival.
  • [MeSH-major] Carcinoma, Adenosquamous / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2009 May;22(5):651-9 [19270646.001]
  • [Cites] Acta Cytol. 1984 Nov-Dec;28(6):733-6 [6594886.001]
  • [Cites] Int J Pancreatol. 2001;29(1):53-8 [11558633.001]
  • [Cites] Ultrastruct Pathol. 1982 Jan-Mar;3(1):17-23 [7071952.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):372-8 [14681946.001]
  • [Cites] J Gastroenterol. 2003;38(12):1171-5 [14714256.001]
  • [Cites] Cancer. 1972 May;29(5):1133-40 [5021607.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2234-48 [167949.001]
  • [Cites] Cancer. 1980 Sep 1;46(5):1192-6 [7214302.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):85-91 [10597404.001]
  • [Cites] Abdom Imaging. 2000 Jul-Aug;25(4):420-3 [10926197.001]
  • [Cites] Diagn Cytopathol. 2001 Jul;25(1):38-42 [11466811.001]
  • [Cites] World J Gastroenterol. 2008 Nov 28;14(44):6765-70 [19058301.001]
  • [Cites] World J Surg Oncol. 2008;6:95 [18764955.001]
  • [Cites] J Am Coll Surg. 2008 Sep;207(3):368-70 [18722942.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):74-7 [18307024.001]
  • [Cites] Drugs. 2007;67(16):2293-310 [17983252.001]
  • [Cites] JOP. 2007;8(3):330-4 [17495363.001]
  • [Cites] Digestion. 2005;72(2-3):104-8 [16172546.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):987-90 [16126885.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):599-603 [10367867.001]
  • [Cites] Acta Cytol. 1998 Nov-Dec;42(6):1451-4 [9850660.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1167-70 [9672355.001]
  • [Cites] Lifetime Data Anal. 1995;1(2):195-204 [9385101.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] J Surg Oncol. 1997 Feb;64(2):159-62 [9047255.001]
  • [Cites] J Surg Oncol. 1991 Jun;47(2):109-16 [2062081.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):72-5 [3522134.001]
  • (PMID = 19801164.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / T32 CA126607
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS433902; NLM/ PMC3556992
  •  go-up   go-down


58. Ma K, Wang TY, He BL, Chang D, Gong M: [Impact of different mediastinal lymphadenectomy on clinical-stage IA non-small cell lung cancer]. Zhonghua Wai Ke Za Zhi; 2008 May 1;46(9):670-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of different mediastinal lymphadenectomy on clinical-stage IA non-small cell lung cancer].
  • OBJECTIVE: To study the role of different lymphadenectomy in the treatment of selected clinical-stage IA non-small cell lung cancer.
  • METHODS: All 115 postoperative patients admitted from January 1997 to May 2002 with pathologic-stage T1 who had been preoperatively diagnosed as clinical-stage I A non-small cell lung cancer were divided into a radical systematic mediastinal lymphadenectomy (LA) group and a mediastinal lymph node sampling (LS) group.
  • Impacts on morbidity, N staging, overall survival (OS) and disease-free survival (DFS) were evaluated in each group respectively.
  • In addition, patients with large cell carcinoma and adenosquamous carcinoma were associated with significantly poor 5-year OS (P < 0.05) , and patients with lymph node metastases were associated with poor 5-year OS as well as 5-year DFS (P < 0.01).
  • CONCLUSIONS: After being intraoperatively identified as T1 stage, patients with lesions of more than 2 cm in clinical-stage IA non-small cell lung cancer should be performed with LA to get a better survival, and patients with lesions of 2 cm or less should be performed with LS to decrease invasion.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymph Node Excision / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956719.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


59. Nolan RC, Chan MT, Heenan PJ: A clinicopathologic review of lethal nonmelanoma skin cancers in Western Australia. J Am Acad Dermatol; 2005 Jan;52(1):101-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 120 NMSC deaths occurred, including 89 caused by squamous cell carcinoma, 22 by Merkel cell carcinoma, and 9 others.
  • When the primary lesion was identified (n = 45), the median survival after diagnosis was 17 months; 75% of patients died within 3 years.
  • Three squamous cell carcinomas were reclassified as adenosquamous carcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Merkel Cell / mortality. Carcinoma, Merkel Cell / pathology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Registries. Survival Analysis. Western Australia / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627087.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Sorbe B, Bohr L, Karlsson L, Bermark B: Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences. Int J Oncol; 2010 Feb;36(2):371-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences.
  • In a series of 131 primary cervical carcinomas in FIGO stages I-IV suitable for combined external pelvic and intraluminal cervical-vaginal brachytherapy predictive and prognostic factors were analyzed with regard to locoregional tumor control, recurrences and survival data.
  • One hundred and seven tumors were squamous cell carcinomas (82%) and 24 adenocarcinomas or adenosquamous carcinomas.
  • Squamous cell carcinomas had complete remission in 96% and adenocarcinomas in 81% (Pearson Chi-square; P=0.00002).
  • A lower FIGO stage, chemoradiotherapy, squamous cell histology, diploid DNA-profile, a higher brachytherapy dose, more brachytherapy fractions and a higher total combined irradiation dose were favorable factors with regard to the risk of tumor recurrences.
  • Chemoradiotherapy therapy versus radiotherapy alone and squamous cell carcinomas versus adenocarcinomas were associated with improved survival rates.
  • [MeSH-major] Brachytherapy / methods. Carcinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy / methods. Uterine Cervical Neoplasms / radiotherapy


61. Ohtsuka K, Ohnishi H, Fujiwara M, Kishino T, Matsushima S, Furuyashiki G, Takei H, Koshiishi Y, Goya T, Watanabe T: Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer; 2007 Feb 15;109(4):741-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
  • BACKGROUND: Tyrosine kinase domain (TKD) gene mutations of the epidermal growth factor receptor gene (EGFR) have proven to be clinically significant in nonsmall-cell lung cancer (NSCLC), particularly in adenocarcinoma.
  • However, TKD mutations together with deletion mutations in the extracellular domain of EGFR (EGFRvIII) have not been fully investigated in NSCLC except for adenocarcinoma.
  • METHODS: EGFR TKD mutations were investigated using direct sequencing and mutation-specific polymerase chain reaction (PCR), and EGFRvIII mutations were examined using reverse transcriptase-PCR in samples from 42 NSCLC patients and 6 NSCLC cell lines excluding adenocarcinoma.
  • RESULTS: EGFR TKD mutations were detected in 1 of 7 (14%) squamous-cell carcinomas with an adenocarcinoma component and 2 of 4 (50%) adenosquamous carcinomas.
  • In contrast, EGFR TKD mutations were not identified in 24 pure squamous-cell carcinomas without any adenocarcinoma component, 7 large-cell carcinomas, or 6 cell lines.
  • EGFRvIII was detected solely in 1 of 7 large-cell carcinomas (14%), but not in 31 squamous-cell carcinomas, 4 adenosquamous carcinomas, or 6 cell lines.
  • CONCLUSIONS: These results suggest that EGFR TKD mutations are found in NSCLCs with an adenocarcinoma element.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238183.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / epidermal growth factor receptor VIII; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


62. Pearl ML, Johnston CM, McMeekin DS: A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix. Gynecol Obstet Invest; 2007;64(4):193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible patients were required to have measurable disease with adequate performance status, bone marrow, renal and hepatic function.
  • Docetaxel 35 mg/m2 was administered intravenously weekly for 3 weeks followed by 1 week off until disease progression or adverse effects prohibited further therapy.
  • Three patients had stable disease up to 6 cycles.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Middle Aged. Oklahoma. Survival Analysis. Treatment Outcome


63. Chen Y, Xu H, Li Y, Wang D, Li J, Yuan J, Liang Z: The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: a prospective analysis of 295 patients. Ann Surg Oncol; 2008 Oct;15(10):2847-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Cervical carcinoma is likely to become one of the most important indications for laparoscopic radical surgery.
  • Of these patients, 43 (14.6%) have died of their disease, and 5 (1.7%) are alive with disease.
  • The overall disease-free survival was 95.2% for Ia, 96.2% for Ib, 84.5% for IIa, 79.4% for IIb, 66.7% for IIIa, and 60.0% for IIIb.
  • CONCLUSION: Laparoscopic radical hysterectomy is a routine, effective treatment for patients with Ia2-IIb cervical carcinoma.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications / etiology. Postoperative Complications / pathology. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome


64. Vieira SC, Sousa RB, Tavares MB, de Abreu BA, Ibiapina JO, de Sousa Oliveira AK, Zeferino LC: Changes in pulse oximetry after patent blue dye injection into the uterine cervix. Ann Surg Oncol; 2008 Oct;15(10):2862-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To evaluate changes in pulse oximetry readings in patients with cervical carcinoma after the injection of patent blue dye into the uterine cervix for sentinel lymph node detection.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / surgery. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / surgery. Female. Humans. Middle Aged. Prognosis. Sentinel Lymph Node Biopsy. Technetium


65. Kodama J, Shinyo Y, Hasengaowa, Kusumoto T, Seki N, Nakamura K, Hongo A, Hiramatsu Y: Loss of basement membrane heparan sulfate expression is associated with pelvic lymph node metastasis in invasive cervical cancer. Oncol Rep; 2005 Jul;14(1):89-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Basement Membrane / metabolism. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Glucuronidase / genetics. Glucuronidase / metabolism. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis


66. Brody JR, Costantino CL, Potoczek M, Cozzitorto J, McCue P, Yeo CJ, Hruban RH, Witkiewicz AK: Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol; 2009 May;22(5):651-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma.
  • Adenosquamous carcinoma of the pancreas is one of the most aggressive forms of pancreatic cancer.
  • Understanding the common molecular and pathologic features of pancreatic adenosquamous carcinomas could provide critical information for identifying therapeutic targets.
  • Herein, we analyzed the pathologic and molecular features of our series of eight pancreatic adenosquamous carcinomas.
  • The majority of the cases had loss of Dpc4 protein and strong nuclear p53 positivity, similar to the molecular signature found in pancreatic ductal adenocarcinoma.
  • The squamous component was positive for p63 staining and thus p63 labeling was helpful in identifying squamous differentiation in adenosquamous carcinomas with an acantholytic growth pattern.
  • In summary, although pancreatic adenosquamous carcinoma and ductal adenocarcinoma have overlapping pathologic and molecular characteristics, there are distinct differences that may be helpful in diagnostic and therapeutic strategies.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Carcinoma, Pancreatic Ductal / genetics. DNA-Binding Proteins / genetics. Pancreatic Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Smad4 Protein / genetics. ras Proteins / genetics


67. Oliva VL, Little JV, Carlson GW: Syringomatous adenoma of the nipple--treatment by central mound resection and oncoplastic reconstruction. Breast J; 2008 Jan-Feb;14(1):102-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been reported under several names including low-grade adenosquamous carcinoma, SA of the nipple, and infiltrating SA of the nipple.
  • Clinical examination and mammographic evidence yield high suspicion for carcinoma and often these lesions are misdiagnosed.
  • [MeSH-minor] Abscess / pathology. Adult. Diagnosis, Differential. Female. Humans. Mammaplasty

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186873.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D, Xiao X: Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax; 2008 Apr;63(4):352-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas.
  • The specific expression of this protein and its cellular distribution were investigated in 145 paraffin embedded lung cancer samples, six benign lung disease and 21 normal lung tissues by immunohistochemistry.
  • RESULTS: Specific expression of both S100A7 mRNA and protein was found in squamous cell carcinomas, adenosquamous carcinomas and large cell lung carcinomas, whereas neither was detected in adenocarcinomas or paired non-cancerous lung tissues.
  • Further immunohistochemical analysis identified positive staining of S100A7 only in squamous cell carcinomas and large cell lung carcinomas, but not in other subtypes of lung cancer and normal lung tissues.
  • Our most important finding is that elevated S100A7 protein could be detected in the sera of patients with squamous cell carcinomas.
  • CONCLUSION: S100A7 was only expressed in squamous cell carcinomas and large cell lung carcinomas and an increase in the level of S100A7 protein in serum may serve as a potential marker for lung cancer diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Calcium-Binding Proteins / metabolism. Carcinoma, Large Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364444.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Neoplasm Proteins; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


69. Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P: Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol; 2009 Jan;4(1):12-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
  • BACKGROUND: Progression of non-small cell lung cancer (NSCLC) from early- to late-stage may signify the accumulation of gene mutations.
  • There also does not seem to be significant differences in the frequency of mutations in EGFR, KRAS, and p53 between early- and advanced-stage disease: 20% versus 24% (p = 0.48), 29% versus 27% (p = 0.75), 10% versus 6% (p = 0.27), respectively.
  • Mutations in EGFR, KRAS and p53 are unlikely to be responsible for the progression of NSCLC from early- to late-stage disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-met / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Suppressor Protein p53 / genetics. ras Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Base Sequence. Biopsy. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. DNA, Neoplasm / genetics. Feasibility Studies. Female. Gene Amplification. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096301.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


70. Toita T, Kodaira T, Uno T, Shinoda A, Akino Y, Mitsumori M, Teshima T: Patterns of pretreatment diagnostic assessment and staging for patients with cervical cancer (1999-2001): patterns of care study in Japan. Jpn J Clin Oncol; 2008 Jan;38(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Diagnostic Imaging / trends. Diagnostic Tests, Routine / trends. Oncology Service, Hospital / utilization. Process Assessment (Health Care) / trends. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / radiotherapy. Cross-Sectional Studies. Female. Humans. Japan. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Staging


71. Okano T, Gemma A, Hosoya Y, Hosomi Y, Nara M, Kokubo Y, Yoshimura A, Shibuya M, Nagashima M, Harris CC, Kudoh S: Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncol Rep; 2006 Mar;15(3):545-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ING1 gene is involved in the regulation of the cell cycle, senescence, and apoptosis and is a novel candidate tumor suppressor gene.
  • To determine whether an alteration in these genes plays a role in carcinogenesis and tumor progression in lung cancer, we screened 30 human lung cancer cell lines and 31 primary lung cancer tumors for mutations in these genes using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing.
  • We also examined the expression of ING1 and ING2 in lung cancer cell lines that either had or lacked a p53 mutation, and in a control bronchial epithelium cell line, using quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR).
  • ING1 expression was up-regulated in all 7 lung cancer cell lines that had a p53 mutation, while the expression of ING2 was down-regulated in 6 of 7 lung cancer cell lines that had a p53 mutation.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Base Sequence. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. DNA Mutational Analysis. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Humans. Intracellular Signaling Peptides and Proteins / genetics. Nuclear Proteins / genetics. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Cytoplasmic and Nuclear / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465410.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Homeodomain Proteins; 0 / ING1 protein, human; 0 / ING2 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


72. Egilmez T, Bal N, Guvel S, Kilinc F, Ozkardes H: Adenosquamous carcinoma of the prostate. Int J Urol; 2005 Mar;12(3):319-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the prostate.
  • Adenosquamous carcinoma of the prostate is an unusual histological variant of prostate cancer.
  • The stimulus for the development of the squamous metaplastic cells had been thought to be related to hormone and/or radiation therapy.
  • This report presents a case of adenosquamous carcinoma of the prostate with abscence of previous hormone or radiation therapy.
  • The case showed negative prostate-specific antigen and high molecular weight cytokeratin staining of the adenocarcinoma component, and negative prostate-specific antigen and positive high molecular weight cytokeratin staining of the squamous cell carcinoma component.
  • The adenocarcinoma component stained intraluminally with periodic acid schiff.
  • The staining features and the distinct localizations of the components with intermingling, but no transition, are against the collision-type tumor theory and support the theory that the adenocarcinoma and squamous components arise de novo from pluripotent stem cells.
  • The patient had a rapid downhill clinical course and died 3 weeks after the diagnosis was made.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15828965.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


73. Malhotra S, Lam S, Man SF, Gan WQ, Sin DD: The relationship between stage 1 and 2 non-small cell lung cancer and lung function in men and women. BMC Pulm Med; 2006;6:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between stage 1 and 2 non-small cell lung cancer and lung function in men and women.
  • BACKGROUND: Reduced forced expiratory volume in one second (FEV1) has been linked to non small cell lung cancer (NSCLC).
  • We divided the cohort into quartiles of predicted FEV1 and using both logistic and linear regression modeling techniques determined whether FEV1 was related to the occurrence of adeno or squamous cell carcinoma in men and women.
  • On average, women were more likely to have adenocarcinoma than were men (72% of all cases of NSCLC in women versus 40% in men; p < 0.001).
  • In men, however, there was an inverse relationship between the risk of adenocarcinoma and FEV1 such that the lowest quartile of FEV1 was 47% less likely to have adenocarcinoma compared with the highest FEV1 quartile (adjusted odds ratio, 0.52; 0.28 to 0.98; p for trend, 0.028).
  • The reverse was observed for squamous cell carcinoma.
  • CONCLUSION: In individuals undergoing lung resection for NSCLC, the risk of adenocarcinoma and squamous cell carcinoma of the lung varies as a function of FEV1, independent of smoking intensity in men but not in women.
  • CLINICAL IMPLICATIONS: These data indicate that women are much more susceptible to adenocarcinoma than are men especially when they have normal or near normal lung function.
  • It may thus be useful to conduct periodic surveillance chest radiographs in asymptomatic female smokers (or ex-smokers) to ascertain peripheral nodules or masses before distant metastases occur since adenocarcinomas tend to metastasize earlier in the disease course than squamous cell carcinomas.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / etiology. Lung / physiology. Lung Neoplasms / etiology. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1996 Oct;17(10):2201-5 [8895489.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3317-20 [10416585.001]
  • [Cites] Thorax. 2005 Jul;60(7):570-5 [15994265.001]
  • [Cites] Exp Lung Res. 2000 Dec;26(8):731-42 [11195467.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):440-3 [11882767.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 May;282(5):L1122-34 [11943679.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1631-6 [12377741.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):21S-49S [12527563.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1604-10 [12738712.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Integr Cancer Ther. 2003 Sep;2(3):238-46 [15035887.001]
  • [Cites] Thorax. 2004 Aug;59(8):679-81 [15282388.001]
  • [Cites] J Allergy Clin Immunol. 2004 Aug;114(2):248-53 [15316498.001]
  • [Cites] Am Rev Respir Dis. 1981 Jun;123(6):659-64 [7271065.001]
  • [Cites] Ann Intern Med. 1986 Oct;105(4):503-7 [3752756.001]
  • [Cites] Ann Intern Med. 1987 Apr;106(4):512-8 [3826952.001]
  • [Cites] Am Rev Respir Dis. 1990 Mar;141(3):613-7 [2310094.001]
  • [Cites] J Natl Cancer Inst. 1990 Aug 15;82(16):1333-9 [2380990.001]
  • [Cites] Am Rev Respir Dis. 1991 Nov;144(5):1202-18 [1952453.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1001-5 [10353732.001]
  • (PMID = 16451726.001).
  • [ISSN] 1471-2466
  • [Journal-full-title] BMC pulmonary medicine
  • [ISO-abbreviation] BMC Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1373665
  •  go-up   go-down


74. Shutoh M, Oue N, Aung PP, Noguchi T, Kuraoka K, Nakayama H, Kawahara K, Yasui W: DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation. Cancer; 2005 Oct 15;104(8):1609-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation.
  • To the authors' knowledge, little is known regarding the involvement of these three genes in gastric carcinoma (GC).
  • METHODS: DNA methylation of 3 retinoic acid-associated genes was analyzed in 42 samples of GC from 42 patients and in 8 GC cell lines by methylation-specific polymerase chain reaction (PCR) analysis.
  • RESULTS: In 7 of 8 GC cell lines, the CRBP1 gene was hypermethylated, and CRBP1 transcription was inactive.
  • In 6 of 8 GC cell lines, the TIG1 gene was hypermethylated, and TIG1 transcription was inactive.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Azacitidine / pharmacology. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Gene Silencing. Genes, Tumor Suppressor. Humans. Intestinal Neoplasms / genetics. Intestinal Neoplasms / pathology. Male. Metaplasia / genetics. Metaplasia / pathology. Middle Aged. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retinol-Binding Proteins, Cellular. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Transcription, Genetic. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16134180.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RARRES1 protein, human; 0 / RBP1 protein, human; 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / Retinoids; 0 / Retinol-Binding Proteins; 0 / Retinol-Binding Proteins, Cellular; 0 / retinoic acid receptor beta; M801H13NRU / Azacitidine
  •  go-up   go-down


75. Horio T, Ogata S, Sugiura Y, Aiko S, Kanai N, Matsunaga H, Maehara T: Cholecystic adenosquamous carcinoma mimicking Mirizzi syndrome. Can J Surg; 2009 Jun;52(3):E71-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholecystic adenosquamous carcinoma mimicking Mirizzi syndrome.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Cholecystolithiasis / diagnosis. Cholestasis / diagnosis. Cholestasis, Extrahepatic / diagnosis. Gallbladder Neoplasms / diagnosis. Jaundice, Obstructive / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Syndrome

  • Genetic Alliance. consumer health - Mirizzi syndrome.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2001 Jan;67(1):11-4 [11206888.001]
  • [Cites] ANZ J Surg. 2006 Apr;76(4):251-7 [16681544.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1493-7 [1516000.001]
  • [Cites] Radiology. 2004 Oct;233(1):234-40 [15333766.001]
  • (PMID = 19503654.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2689754
  •  go-up   go-down


76. Fujiu K, Sakuma H, Shio Y, Suzuki H, Mori M: [A case of non-Hodgkin's lymphoma after chemotherapy for cancer of unknown origin]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1907-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography(CT)scans showed a swelling of the superior mediastinal lymph node and a tumor of the right lobe of thyroid gland.
  • Pathological findings of the lymph node showed adenosquamous cell carcinoma, but no malignant lesion was found in the thyroid gland.
  • Post-operative systemic survey failed to identify the origin of the adenosquamous cell carcinoma.
  • Seven months later, CT and positron emission tomography revealed swelling of the mediastinal lymph nodes and a tumor in the left abdominal tumor.
  • An open biopsy of the abdominal tumor demonstrated non-Hodgkin's lymphoma, mature B cell type, follicular lymphoma, grade 1.
  • Radiotherapy was done for the malignant lymphoma, and radiochemotherapy for the mediastinal lymph nodes.
  • Seven months later, the patient died of systemic metastases of the adenosquamous cell carcinoma.
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Biopsy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Combined Modality Therapy. Humans. Male. Tomography, X-Ray Computed. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011340.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Sasieni P, Castanon A, Cuzick J: Screening and adenocarcinoma of the cervix. Int J Cancer; 2009 Aug 1;125(3):525-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening and adenocarcinoma of the cervix.
  • Although there can be no doubt about its effectiveness in preventing squamous-cell carcinoma, there is little evidence of any benefit on adenocarcinoma and adenosquamous carcinoma of the cervix, and many authors have concluded that it is ineffective.
  • Among 3,305 cases with known histology, 641 had adenocarcinoma and 133 adenosquamous carcinoma.
  • The risk reduction associated with 3-yearly screening was greater for squamous carcinoma (75%, 95%CI 71-79%) and adenosquamous carcinoma (83%, 95%CI 68-91%) than for adenocarcinoma (43%, 95%CI 24-58%).
  • Among stage 1B+ cases, 83% (335/406) of women with adenocarcinoma had been screened within 10 years of diagnosis.
  • This is very similar to controls (82%, 3,292/3,965), but much higher than in women with squamous carcinoma (57%, 852/1,493).
  • Incidence of adenocarcinoma was low within 2.5 years of a negative smear (OR 2.3, 95%CI 0.15-0.34), but was no different from the background rates 4.5-5.5 years after a negative smear.
  • We conclude that screening has reduced the incidence of adenocarcinoma of the cervix, but the prognostic value of cytology is less (in both magnitude and duration) for adenocarcinoma than for squamous carcinoma.
  • The impact of screening on adenosquamous carcinoma is similar to its impact on squamous carcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / prevention & control. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Mass Screening. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / prevention & control
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / prevention & control. Case-Control Studies. Colposcopy. Female. Great Britain / epidemiology. Humans. Incidence. Logistic Models. Middle Aged. Neoplasm Invasiveness


78. Zhao C, Florea A, Austin RM: Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med; 2010 Jan;134(1):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells.
  • CONTEXT: Atypical glandular cell (AGC) Papanicolaou (Pap) test interpretations are challenging.
  • Most biopsy findings are benign, but AGC results may also reflect highly significant noninvasive neoplastic and malignant histologic outcomes.
  • Among the 75 cases with hrHPV+ AGC results, 13 (17.3%) had cervical intraepithelial neoplasia grades 2/3, 10 (13.3%) had adenocarcinoma in situ, and 3 (4.0%) had cervical invasive adenocarcinoma, whereas for 234 women with hrHPV(-) results, 1 (0.4%) had cervical intraepithelial neoplasia grades 2/3, 1 (0.4%) had adenocarcinoma in situ, 1 each (0.4%) had cervical adenocarcinoma and ovarian carcinoma, and 8 (3.4%) had endometrial carcinoma.
  • CONCLUSIONS: Positive hrHPV AGC results were most strongly associated with cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ in women younger than 50 years.
  • Positive hrHPV AGC results were also present in all 3 cases of invasive cervical adenocarcinoma in women younger than 50 years.
  • Of note, hrHPV(-) AGC results were present in 10 of 13 carcinomas (76.9%) detected after AGC Pap tests, all in women 40 years or older with endometrial adenocarcinomas (n = 8), ovarian carcinoma (n = 1), and cervical adenosquamous carcinoma in a woman (n = 1) in her 50s.
  • Testing for hrHPV after AGC Pap testing was most helpful in the detection of cervical intraepithelial neoplasia grades 2/3, adenocarcinoma in situ, and invasive cervical adenocarcinomas in women younger than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. DNA, Viral. Papanicolaou Test. Papillomaviridae / genetics. Uterine Cervical Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / virology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / virology. Female. Humans. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / virology. Retrospective Studies. Risk Factors. Sensitivity and Specificity. Young Adult


79. Schilder RJ, Blessing J, Cohn DE: Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol; 2005 Jan;96(1):103-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
  • PURPOSE: A multicenter study was conducted to evaluate the activity and toxicity of gemcitabine in patients with previously treated non-squamous cell carcinoma of the uterine cervix.
  • PATIENTS AND METHODS: Eligible patients were required to have measurable disease with a GOG performance status of 0-2 and adequate bone marrow, renal, and hepatic function.
  • Histologic confirmation of the primary diagnosis was mandatory.
  • Patients were required to have received one prior chemotherapy regimen for metastatic, persistent or recurrent disease.
  • The initial dosage of gemcitabine was 800 mg/m(2) weekly times three with 1 week off until progressive disease or adverse side effects prohibited further therapy.
  • Doses were escalated or reduced based on the disease toxicity experiences during the previous cycle.
  • The overall response rate (1 partial response) was 4.5% with 36.4% of patients having stable disease.
  • CONCLUSIONS: Gemcitabine as a single agent had minimal activity in previously treated patients with non-squamous cell carcinoma of the uterine cervix.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589587.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 13630; United States / NCI NIH HHS / CA / CA 23073; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 28160; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / CA13633; United States / NCI NIH HHS / CA / CA15977
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


80. Barussaud ML, Meurette G, Cassagnau E, Dupasc B, Le Borgne J: Mixed adenocarcinoma and squamous cell carcinoma arising in a gastric duplication cyst. Gastroenterol Clin Biol; 2008 Feb;32(2):188-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed adenocarcinoma and squamous cell carcinoma arising in a gastric duplication cyst.
  • Malignant transformation of duplication cyst is a rare condition.
  • The histologic examination revealed a gastric duplication cyst infiltrated with both adenocarcinoma and squamous cell carcinoma.
  • The patient died six months after complete macroscopic resection of the lesion, with metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cysts / pathology. Neoplasms, Multiple Primary / pathology. Stomach / abnormalities. Stomach Diseases / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic / pathology. Fatal Outcome. Female. Follow-Up Studies. Humans. Peritoneal Neoplasms / secondary


81. Yasuda M, Terai Y, Sekijima T, Sasaki H, Yamashita Y, Kanemura M, Ohmichi M: Successful pregnancy after conservative surgery for stage IA endometrial cancer in a young woman. Fertil Steril; 2009 Mar;91(3):936.e13-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Adenosquamous / surgery. Endometrial Neoplasms / surgery. Fertility. Hysteroscopy

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062001.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


82. Carvalho L: Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol; 2009 Nov-Dec;15(6):1101-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry.
  • The current state of molecular knowledge on lung cancer demands a histological classification which goes beyond small-cell and non-small-cell carcinoma to provide support for tailored therapy in aiding in understanding of the drugs currently available.
  • As diagnosis and follow-up in the vast majority of lung cancer cases is based on biopsies and cytology samples, Immunohistochemical Bronchial Pulmonary Carcinoma Classification (IBPCC) is necessary to reveal the raft of characteristics available.
  • The immunohistochemical panel clarifies the main morphology and cytology characteristics to maintain the leading histological types as squamous cell carcinoma (high weight molecular cytokeratins/HWMC), adenosquamous carcinoma (CK7, TTF1, HWMA), neuroendocrine carcinoma (Chrg, Syn, CD56, TTF1, Ki67), adenocarcinoma (CK7, CK20, TTF1) and bring the polymorphic and pleomorphic carcinomas under a single banner of pleomorphic carcinoma (Ck7, TTF1, HWMC, VMT, Desmin, Actin) which shelters large cell carcinomas and sarcomatoid carcinomas.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Bronchial Neoplasms / classification. Bronchial Neoplasms / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859629.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Portugal
  • [Number-of-references] 80
  •  go-up   go-down


83. Kadokura M, Kamio Y, Kitami A, Nakajima H, Kushihashi T, Shiokawa A, Nonaka M: [Completion pneumonectomy 9 years after middle lobectomy for adenocarcinoma]. Kyobu Geka; 2005 May;58(5):361-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Completion pneumonectomy 9 years after middle lobectomy for adenocarcinoma].
  • Bronchofiberscopic cytology revealed squamous cell carcinoma.
  • Histopathologically, resected specimens represented adenosquamous carcinoma similar to the prior lesion from the middle lobe, and examination revealed that the tumor represented a recurrence following middle lobectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Neoplasms, Second Primary / surgery. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881232.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


84. Martínez-Monge R, Nagore G, Cambeiro M, Garrán C, Villafranca E, Jurado M: Intravaginal 1-week high-dose-rate brachytherapy alone for Stages I-II endometrial cancer. Brachytherapy; 2007 Jul-Sep;6(3):195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: From December 1999 to February 2005, 50 patients with International federation of gynecology and obstetrics Stages IA-IIB endometrioid endometrial adenocarcinoma were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by postoperative HDR brachytherapy alone.
  • RESULTS: After a median followup of 37 months (range 12-80), the overall survival and disease-free survival were 96%.
  • [MeSH-major] Adenocarcinoma, Clear Cell / radiotherapy. Brachytherapy / methods. Carcinoma, Adenosquamous / radiotherapy. Endometrial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681240.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Selvaggi L, Loizzi V, DI Gilio AR, Nardelli C, Cantatore C, Cormio G: Neoadjuvant chemotherapy in cervical cancer: a 67 patients experience. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):631-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-seven patients received neoadjuvant chemotherapy: 34 had stage I disease, 28 had stage II disease, and 5 had stage III disease.
  • Clinical response to neoadjuvant chemotherapy occurred in 61 patients, including six with complete and 55 with partial response; five women showed stable disease and one progressed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Squamous Cell / drug therapy. Neoadjuvant Therapy. Uterine Cervical Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681738.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


86. Kodama K, Okami J, Maeda J, Tokunaga T, Kanzaki R, Fujiwara A, Higashiyama M: [Complete resection of Pancoast tumor following induction chemoradiotherapy improves survival]. Kyobu Geka; 2010 Jan;63(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Pancoast tumors are some of the most challenging thoracic malignant diseases to treat because of their proximity to vital structures at the thoracic inlet.
  • There were 10 each of squamous cell carcinoma and adenocarcinoma, 2 large cell carcinoma, and 1 adenosquamous carcinoma.
  • RESULTS: A posterior approach was employed in 14 patients, an anterior approach in 7, and a combined anterior and posterior approach in 2.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077826.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Cibula D, Sláma J, Velechovská P, Fischerova D, Zikán M, Pinkavová I, Hill M: Factors affecting spontaneous voiding recovery after radical hysterectomy. Int J Gynecol Cancer; 2010 May;20(4):685-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariate analysis revealed 3 significant parameters: procedure radicality (P < 0.001), type of procedure (radical hysterectomy vs radical trachelectomy; P < 0.05), and a negative correlation with body mass index (P < 0.05).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Adenosquamous / surgery. Hysterectomy / adverse effects. Postoperative Complications. Urinary Incontinence / etiology. Urination. Uterine Cervical Neoplasms / surgery


88. Sato S, Itamochi H, Shimada M, Fujii S, Naniwa J, Uegaki K, Sato S, Nonaka M, Ogawa T, Kigawa J: Preoperative and intraoperative assessments of depth of myometrial invasion in endometrial cancer. Int J Gynecol Cancer; 2009 Jul;19(5):884-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Preoperative and intraoperative assessments of myometrial invasion (MI) are commonly used for planning surgical procedures such as dissection of the para-aortic node; however, the assessments often differ from the final diagnosis determined by pathological examination.
  • Regarding the diagnosis of greater than 50% MI depth, the accuracy, the sensitivity, and the specificity of the MRI assessment were 83.2%, 75.0%, and 85.7%, respectively.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Humans. Hysterectomy. Intraoperative Care. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Preoperative Care. Prognosis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574778.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Nagy PS, Sipos J: [Glassy cell carcinoma of the endometrium: case report and review of the literature]. Orv Hetil; 2009 Jun 21;150(25):1173-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glassy cell carcinoma of the endometrium: case report and review of the literature].
  • The authors presented a case of a 68-year-old woman with glassy cell carcinoma of the endometrium in FIGO stage IA, treated with hysterectomy, bilateral salpingo-oophorectomy and radiation therapy.
  • The patient was alive and disease free at the end of 2 years of follow up.
  • Glassy cell carcinoma of the endometrium is a rare neoplasm, with 13 previously cases reported in the literature.
  • Although glassy cell carcinoma is considered to be a poor differentiated variant of adenosquamous carcinoma, its real nature is still debated.
  • In order to establish correct prognosis for this rare entity and to evaluate the nature and clinical significance of glassy cell carcinoma detailed analysis of more cases is required.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / therapy. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19497839.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 15
  •  go-up   go-down


90. Baltazar F, Filho AL, Pinheiro C, Moreira MA, Queiroz GS, Oton GJ, Júnior AF, Ribeiro LF, Schmitt FC: Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. Int J Gynecol Pathol; 2007 Jul;26(3):235-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas.
  • This study was designed to evaluate the significance of cyclooxygenase (COX)-2 and epidermal growth factor receptor (EGFR) expression in a series of cervical adenocarcinoma (AC), cervical adenosquamous carcinoma (ASC), and cervical squamous cell carcinoma (SCC).
  • One hundred thirty cases of cervical carcinoma (30 ASC, 50 AC, and 50 SCC) were analyzed for COX-2 and EGFR expressions using specific primary antibodies.
  • There was no significant correlation between COX-2 and EGFR expressions and age at diagnosis, recurrence, distant metastasis, and/or positive status of regional lymph nodes, neither between COX-2 and EGFR coexpression and the clinical data analyzed.
  • [MeSH-major] Adenocarcinoma / enzymology. Carcinoma, Adenosquamous / enzymology. Carcinoma, Squamous Cell / enzymology. Cyclooxygenase 2 / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis. Uterine Cervical Neoplasms / enzymology


91. Yasuda S, Kojima A, Maeno Y, Oki N, Miyahara Y, Sudo T, Takekida S, Yamaguchi S, Nishimura R: Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lymphnode metastasis. Kobe J Med Sci; 2006;52(1-2):9-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lymphnode metastasis.
  • From January 1990 to December 2004, the prognosis of 28 patients with stage Ib1 adenosquamous cell carcinoma (ASC) were assessed in comparison with those of matched counterparts of pure adenocarcinoma (ADC) and squamous cell carcinoma (SCC).
  • There was also no significant difference in the incidence of lymphatic or vascular space involvement (LVSI) and depth of stromal invasion between three cell types.
  • Since the tumor sizes of all ASC cases examined in this study were less than 4 cm, the prognoses were compared among stage Ib1 disease according to the classification system of the International Federation of Gynecology and Obstetrics (FIGO).
  • While all 9 patients in the low-risk group are alive without disease, 7 of the 19 patients in the high-risk group developed recurrence.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lymphatic Metastasis / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Pelvis. Prognosis. Retrospective Studies. Survival Rate


92. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Huh WK, Jaggernauth W, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR 3rd, Morgan M, Morgan RJ Jr, Powell CB, Remmenga SW, Reynolds RK, Secord AA, Small W Jr, Teng N, National Comprehensive Cancer Network: Cervical cancer. J Natl Compr Canc Netw; 2008 Jan;6(1):14-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Decision Trees. Female. Humans. Neoplasm Staging


93. Okami J, Higashiyama M, Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Miyaoka E, Japanese Joint Committee of Lung Cancer Registry: Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications. J Thorac Oncol; 2009 Oct;4(10):1247-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications.
  • INTRODUCTION: This retrospective study was designed to identify the predictors of long-term survival and the risk factors for complications after surgery in patients aged 80 years or older with clinical (c)-stage I non-small cell lung cancer.
  • The data of 367 patients aged 80 years or older with c-stage I non-small cell lung cancer were analyzed for prognostic factors and risk factors for postoperative complications.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Comorbidity. Female. Humans. Lymph Node Excision. Male. Mediastinum / surgery. Neoplasm Staging. Postoperative Complications. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome


94. Jiang L, Ji N, Zhou Y, Li J, Liu X, Wang Z, Chen Q, Zeng X: CAL 27 is an oral adenosquamous carcinoma cell line. Oral Oncol; 2009 Nov;45(11):e204-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CAL 27 is an oral adenosquamous carcinoma cell line.
  • CAL 27 is one of the most frequently used cell lines in the field of oral squamous cell carcinoma (OSCC) studying.
  • Then, we performed tumor formation assay, HE staining and immunohistochemistry assay to further study the growing characteristics and histopathological diagnosis of CAL 27 xenografts.
  • The CAL 27 xenografts were then diagnosed as oral adenosquamous carcinomas.
  • Thus CAL 27 appears to be an oral adenosquamous carcinoma cell line.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Cell Line, Tumor / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Carcinoma / pathology. Carcinoma, Squamous Cell. Head and Neck Neoplasms / pathology. Humans. Neoplasms, Squamous Cell / pathology. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19631575.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Carcinoma, squamous cell of head and neck
  •  go-up   go-down


95. Picozzi G, Paci E, Lopez Pegna A, Bartolucci M, Roselli G, De Francisci A, Gabrielli S, Masi A, Villari N, Mascalchi M: Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ''Italung-CT''. Radiol Med; 2005 Jan-Feb;109(1-2):17-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One (1.6%) prevalent lung cancer (adenosquamous carcinoma) and one (2.2%) incident lung cancer (small cell cancer at the first annual examination) were observed, as well as a pulmonary localisation of Hodgkin's lymphoma (at the second annual test).

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15729183.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


96. Mori T, Hosokawa K, Sawada M, Kuroboshi H, Tatsumi H, Koshiba H, Okubo T, Kitawaki J: Neoadjuvant weekly carboplatin and paclitaxel followed by radical hysterectomy for locally advanced cervical cancer: long-term results. Int J Gynecol Cancer; 2010 May;20(4):611-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two had complete response, 4 had stable disease, and the remaining patients had partial response; progressive disease was not seen in this study.
  • There was no significant correlation in survival between preoperative staging and cell type, whereas larger initial tumor size and lymph node metastasis tended to be negatively correlated with survival.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenosquamous / therapy. Carcinoma, Squamous Cell / therapy. Hysterectomy. Neoadjuvant Therapy. Uterine Cervical Neoplasms / therapy


97. Ballester M, Dubernard G, Rouzier R, Barranger E, Darai E: Use of the sentinel node procedure to stage endometrial cancer. Ann Surg Oncol; 2008 May;15(5):1523-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lymph node status is a major prognostic factor and a criterion for adjuvant therapy in endometrial cancer.
  • Among the ten women with a positive SN, three of the four women with a grade 1 tumour at biopsy had grade 2-3 disease on final histology.
  • Given the limited capacity of MR imaging to detect myometrial invasion, and of biopsy to determine histological grade, our results support the systematic use of the SN procedure in women with endometrial cancer, including those with presumed early-stage disease and/or well-differentiated tumours.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / epidemiology. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. False Negative Reactions. Female. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Jul;15(7):1815-7 [18473144.001]
  • (PMID = 18322758.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Odashiro M, Lima MG, Miiji LN, Odashiro DN, Carvalho GV, Prates Campos JC, Odashiro AN: Infiltrating syringomatous adenoma of the nipple. Breast J; 2009 Jul-Aug;15(4):414-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologically, it must be distinguished from florid papillomatosis, adenosquamous carcinoma, adenoid cystic carcinoma and sclerosing syringomatous carcinoma.
  • Some ducts were slightly dilated with squamous metaplasia.
  • Patient has no signs of progression of disease in 1 year of follow-up.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470133.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Tong SY, Lee YS, Park JS, Namkoong SE: Human papillomavirus genotype as a prognostic factor in carcinoma of the uterine cervix. Int J Gynecol Cancer; 2007 Nov-Dec;17(6):1307-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus genotype as a prognostic factor in carcinoma of the uterine cervix.
  • The clinical implications of specific human papillomavirus (HPV) types in invasive cervical carcinomas are only now beginning to be appreciated.
  • The objective of this study was to determine the clinical implications and prognostic value of the HPV genotype in cervical carcinomas.
  • The HPV-16-related types were detected more frequently in patients with squamous cell carcinomas, whereas the HPV-18-related types were more prevalent in cases of adenocarcinomas and adenosquamous carcinomas (P < 0.05).
  • We conclude that neither the presence nor type of HPV DNA bears any prognostic significance in cases of cervical carcinoma.
  • [MeSH-major] Carcinoma / virology. Papillomaviridae / genetics. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425678.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. Haack S, Pedersen EM, Jespersen SN, Kallehauge JF, Lindegaard JC, Tanderup K: Apparent diffusion coefficients in GEC ESTRO target volumes for image guided adaptive brachytherapy of locally advanced cervical cancer. Acta Oncol; 2010 Oct;49(7):978-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffusion weighted imaging (DWI) and the derived apparent diffusion coefficient (ADC) may add additional biological information on tumour cell density.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Squamous Cell. Diffusion Magnetic Resonance Imaging / methods. Guidelines as Topic. Image Processing, Computer-Assisted / methods. Radiotherapy Planning, Computer-Assisted / methods. Tumor Burden. Uterine Cervical Neoplasms
  • [MeSH-minor] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / radiotherapy. Diffusion. Disease Progression. Dose Fractionation. Female. Humans. Models, Theoretical. Neoplasm Staging. Organ Size. Radiation Dosage






Advertisement